Pharmaceutical formulations and dosage regimens of multispecific binding proteins that bind to HER2, NKG2D and CD16 for cancer treatment
By developing multispecific binding protein drug preparations that combine HER2 and NKG2D, the shortcomings of HER2 overexpression cancer treatment in the prior art have been solved, effective targeting of HER2 overexpression cancer cells and activation of natural killer cells have been achieved, and the The therapeutic effect of locally advanced or metastatic solid tumors.
Patent Information
- Application Number
- CN202410920352.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-10-18
- Filing Date
- 2020-08-28
- Publication Date
- 2024-11-12
AI Technical Summary
Existing cancer treatments are difficult to effectively target HER2 overexpressing cancers, especially in locally advanced or metastatic solid tumors, and immunotherapy is insufficient in terms of safety and efficacy.
A multispecific binding protein pharmaceutical preparation has been developed, including single-strand variable fragments (scFv) that bind HER2, Fabs that bind NKG2D, and antibody Fc domains, for targeting HER2 overexpression by optimizing components and dosage regimens. Cancer cells and activated natural killer cells.
This drug preparation can effectively target HER2 overexpressed cancer cells, activate natural killer cells, promote cancer cell destruction, and improve the safety and efficacy of treatment, especially in locally advanced or metastatic solid tumors.
Smart Images

Figure CN118924895A_ABST
Abstract
Description
[0001] Divisional application
[0002] This application is a divisional application of the Chinese invention patent application with application number 202080075846.5, application date August 28, 2020, and invention name “Pharmaceutical preparations and dosage regimens of multi-specific binding proteins binding HER2, NKG2D and CD16 for cancer treatment”.
[0003] CROSS REFERENCE TO RELATED APPLICATIONS
[0004] This application claims the benefit of and priority to U.S. Provisional Patent Application No. 62 / 894,047 filed on August 30, 2019, U.S. Provisional Patent Application No. 62 / 895,320 filed on September 3, 2019, and U.S. Provisional Patent Application No. 62 / 916,935 filed on October 18, 2019, the disclosure of each of which is incorporated herein by reference in its entirety for all purposes.
[0005] Sequence Listing
[0006] This application contains a sequence listing submitted electronically in ASCII format and incorporated herein by reference in its entirety. The ASCII copy generated on August 27, 2020 is named DFY-078WO_SL.txt and is 194,972 bytes in size. Technical Field
[0007] The present disclosure generally relates to pharmaceutical formulations having a single chain variable fragment (scFv) that binds epidermal growth factor receptor 2 (ErbB2 or HER2), a Fab that binds NKG2D, and a multispecific binding protein of an antibody Fc domain, and dosage regimens of such multispecific binding proteins and pharmaceutical formulations for treating cancer, such as locally advanced or metastatic solid tumors. Background Art
[0008] Although a large number of research attempts and scientific progress in treating cancer have been reported in the literature, the disease remains a significant health problem. Cancer immunotherapy is being developed to utilize the patient's own immune system to promote the destruction of cancer cells. Immune cells activated by cancer immunotherapy include T cells and natural killer (NK) cells. For example, bispecific T-cell engagers are designed to direct T-cells against tumor cells, thereby producing cytotoxicity to the tumor cells. Bispecific antibodies that bind NK cells and tumor-associated antigens (TAAs) have also been created for cancer treatment (see, e.g., WO 2016 / 134371).
[0009] HER2 is a transmembrane glycoprotein in the epidermal growth factor receptor family. It is a receptor tyrosine kinase and regulates cell survival, proliferation and growth. HER2 plays an important role in human malignancies. The ERBB2 gene is amplified or overexpressed in approximately 30% of human breast cancers. Patients with breast cancers that overexpress HER2 have substantially lower overall survival and shorter disease-free intervals than patients with cancers that do not overexpress HER2. In addition, overexpression of HER2 leads to an increase in breast cancer metastasis. Overexpression of HER2 is also known to occur in many other cancer types, including ovarian, esophageal, bladder and gastric cancers, salivary duct carcinomas, lung adenocarcinomas, and invasive uterine cancers, such as uterine serous endometrial carcinoma.
[0010] Multispecific binding proteins that bind to HER2 and one or more immune cell surface proteins have been studied. For example, WO 2018 / 152518 describes multispecific binding proteins that bind to HER2, NKG2D, and CD16. The present disclosure complements these developments and provides clinical methods for treating patients with the desired safety and efficacy using cancer immunotherapies that specifically target HER2, including dosage regimens. In addition, the present disclosure complements early developments in the field by providing formulations that are sufficiently stable and suitable for administration to patients containing such cancer immunotherapies. Summary of the invention
[0011] The present disclosure provides a pharmaceutical preparation comprising a multispecific binding protein having a scFv that binds to HER2, a Fab that binds to NKG2D, and an antibody Fc domain, wherein the ingredients in the preparation are optimized for the stability of the multispecific binding protein. Also provided is a dosage regimen for using the multispecific binding protein and the pharmaceutical preparation in the treatment of cancer, such as locally advanced or metastatic solid tumors.
[0012] Therefore, in one aspect, the present disclosure provides a pharmaceutical formulation with a pH of 5.5 to 6.5, comprising histidine, polysorbate, a sugar or a sugar alcohol, and a multispecific binding protein comprising an antibody Fc domain, a Fab that binds NKG2D, and a single-chain variable fragment (scFv) that binds HER2.
[0013] In certain embodiments, the concentration of histidine in the pharmaceutical formulation is 10 to 25 mM. In certain embodiments, the concentration of histidine in the pharmaceutical formulation is about 20 mM.
[0014] In certain embodiments, the sugar or sugar alcohol is a disaccharide. In certain embodiments, the disaccharide is sucrose. In certain embodiments, the sugar or sugar alcohol is a sugar alcohol derived from a monosaccharide. In certain embodiments, the sugar alcohol derived from a monosaccharide is sorbitol. In certain embodiments, the concentration of the sugar or sugar alcohol in the pharmaceutical preparation is 200 to 300 mM. In certain embodiments, the concentration of the sugar or sugar alcohol in the pharmaceutical preparation is about 250 mM.
[0015] In certain embodiments, the polysorbate is polysorbate 80. In certain embodiments, the concentration of polysorbate 80 in the pharmaceutical formulation is 0.005% to 0.05%. In certain embodiments, the concentration of polysorbate 80 in the pharmaceutical formulation is about 0.01%.
[0016] In certain embodiments, NaCl, if present, is at a concentration of about 10 mM or less in the pharmaceutical formulation. In certain embodiments, NaCl, if present, is at a concentration of about 1 mM or less in the pharmaceutical formulation.
[0017] In certain embodiments, the pH of the pharmaceutical formulation is between 5.8 and 6.2. In certain embodiments, the pH of the pharmaceutical formulation is between 5.95 and 6.05.
[0018] In certain embodiments, the concentration of the multispecific binding protein in the pharmaceutical formulation is about 10 to about 20 mg / mL.
[0019] In certain embodiments, greater than 94% of the multispecific binding protein has a native conformation after 3 weeks incubation at 50°C as determined by size exclusion chromatography. In certain embodiments, less than 4% of the multispecific binding protein forms high molecular weight complexes after 3 weeks incubation at 50°C as determined by size exclusion chromatography.
[0020] In another aspect, the present disclosure provides use of the pharmaceutical formulation disclosed herein in treating cancer. In certain embodiments, the pharmaceutical formulation is diluted with a 0.9% NaCl solution before use.
[0021] On the other hand, the present disclosure provides a method for treating cancer, comprising administering a multispecific binding protein to a subject in need thereof on day 1, day 8, and day 15 of an initial 4-week treatment cycle, wherein the multispecific binding protein comprises: (a) a Fab that binds NKG2D; (b) a scFv that binds HER2; and (c) an antibody Fc domain.
[0022] In certain embodiments, the method further comprises administering the multispecific binding protein to the subject in one or more subsequent 4-week treatment cycles after the initial treatment cycle, wherein the multispecific binding protein is administered on day 1 and day 15 in each subsequent treatment cycle. In certain embodiments, each of the doses comprises a -5 mg / kg, 1.6×10 -4 mg / kg, 5.2×10 -4 mg / kg, 1.6×10 -3 mg / kg, 5.2×10 -3 mg / kg, 1.6×10 -2 mg / kg, 5.2×10 -2 mg / kg, 1.6×10 -1 In some embodiments, the multispecific binding protein is administered by intravenous infusion.
[0023] In certain embodiments, the multispecific binding proteins are used as monotherapy.
[0024] In certain embodiments, the method further comprises administering an anti-PD-1 antibody to the subject. In certain embodiments, the anti-PD-1 antibody is pembrolizumab. In certain embodiments, 200 mg of pembrolizumab is administered on day 1 of the initial treatment cycle. In certain embodiments, if the subject receives one or more subsequent treatment cycles, 200 mg of pembrolizumab is administered once every three weeks in the subsequent treatment cycles.
[0025] In certain embodiments, the cancer is HER2 positive when measured by immunohistochemistry. In certain embodiments, the HER2 level in the cancer is scored as at least 1+ when measured by immunohistochemistry. In certain embodiments, the HER2 level in the cancer is scored as 2+ or 3+. In certain embodiments, the HER2 level in the cancer is scored as 3+.
[0026] In some embodiments, the cancer has an amplification of the ERBB2 gene. In some embodiments, the ERBB2 gene amplification is determined by fluorescent in situ hybridization. In some embodiments, the ERBB2 gene amplification is determined by DNA sequencing.
[0027] In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is a locally advanced or metastatic solid tumor. In some embodiments, the cancer is selected from gastric cancer, colorectal cancer, non-small cell lung cancer (NSCLC), head and neck cancer, biliary tract cancer, glioblastoma, sarcoma, uterine cancer, cervical cancer, ovarian cancer, esophageal cancer, squamous cell carcinoma of the skin, prostate cancer, salivary gland cancer, breast cancer, pancreatic cancer and gallbladder cancer. In some embodiments, the cancer is urothelial bladder cancer or metastatic breast cancer.
[0028] The following features may be incorporated into any of the embodiments described above:
[0029] In certain embodiments, the Fab comprises a heavy chain variable domain and a light chain variable domain, wherein (a) the heavy chain variable domain comprises a complementarity determining region 1 (CDR1), a complementarity determining region 2 (CDR2) and a complementarity determining region 3 (CDR3) sequence represented by the amino acid sequences of SEQ ID NOs: 168, 96 and 188, respectively; and (b) the light chain variable domain comprises a CDR1, a CDR2 and a CDR3 sequence represented by the amino acid sequences of SEQ ID NOs: 99, 100 and 101, respectively.
[0030] In certain embodiments, (a) the heavy chain variable domain comprises CDR1, CDR2 and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 168, 96 and 169, respectively; and (b) the light chain variable domain comprises CDR1, CDR2 and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 99, 100 and 101, respectively. In certain embodiments, the heavy chain variable domain of the Fab comprises an amino acid sequence at least 90% identical to SEQ ID NO: 94, and the light chain variable domain comprises an amino acid sequence at least 90% identical to SEQ ID NO: 98. In certain embodiments, the heavy chain variable domain of the Fab comprises the amino acid sequence of SEQ ID NO: 94, and the light chain variable domain comprises the amino acid sequence of SEQ ID NO: 98.
[0031] In certain embodiments, the scFv comprises a heavy chain variable domain and a light chain variable domain, wherein (a) the heavy chain variable domain comprises CDR1, CDR2 and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 115, 116 and 117, respectively; and (b) the light chain variable domain comprises CDR1, CDR2 and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 119, 120 and 121, respectively. In certain embodiments, the heavy chain variable domain of the scFv comprises an amino acid sequence at least 90% identical to SEQ ID NO: 195, and the light chain variable domain of the scFv comprises an amino acid sequence at least 90% identical to SEQ ID NO: 196. In certain embodiments, the heavy chain variable domain of the scFv comprises an amino acid sequence of SEQ ID NO: 195, and the light chain variable domain of the scFv comprises an amino acid sequence of SEQ ID NO: 196.
[0032] In certain embodiments, the light chain variable domain of the scFv is connected to the heavy chain variable domain of the scFv via a flexible linker. In certain embodiments, the flexible linker comprises the amino acid sequence of SEQ ID NO: 143. In certain embodiments, the flexible linker consists of the amino acid sequence of SEQ ID NO: 143. In certain embodiments, the light chain variable domain of the scFv is placed at the N-terminus of the heavy chain variable domain of the scFv.
[0033] In certain embodiments, the heavy chain variable domain of the scFv forms a disulfide bond with the light chain variable domain of the scFv. In certain embodiments, the disulfide bond is formed between C44 of the heavy chain variable domain and C100 of the light chain variable domain.
[0034] In certain embodiments, the scFv comprises the amino acid sequence of SEQ ID NO:139.
[0035] In some embodiments, the antibody Fc domain comprises a first antibody Fc sequence connected to the Fab and a second antibody Fc sequence connected to the scFv. In some embodiments, the first antibody Fc sequence is connected to the heavy chain portion of the Fab. In some embodiments, the scFv is connected to the second antibody Fc sequence by a hinge comprising Ala-Ser.
[0036] In certain embodiments, the first and second antibody Fc sequences each comprise the hinge and CH2 domains of a human IgG1 antibody. In certain embodiments, the first and second antibody Fc sequences each comprise an amino acid sequence that is at least 90% identical to amino acids 234-332 of a wild-type human IgG1 antibody.
[0037] In certain embodiments, the first and second antibody Fc sequences comprise different mutations that promote heterodimerization. In certain embodiments, the first antibody Fc sequence is a human IgG1 Fc sequence comprising K360E and K409W substitutions. In certain embodiments, the second antibody Fc sequence is a human IgG1 Fc sequence comprising Q347R, D399V and F405T substitutions.
[0038] In certain embodiments, the multispecific binding protein comprises (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 141; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 140; and (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO: 142.
[0039] Other embodiments and details of the present disclosure are presented below. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Figure 1 A trispecific antibody (TriNKET) is described that contains a scFv that binds HER2, a Fab that targets NKG2D, and a heterodimeric antibody Fc domain that binds CD16 ("F3'-TriNKET" format). In an exemplary embodiment, the Fc domain attached to the Fab fragment contains mutations K360E and K409W, and the Fc domain attached to the scFv contains matching mutations Q347R, D399V, and F405T for forming Fc heterodimers (in Figure 1 In another exemplary embodiment, the Fc domain attached to the Fab fragment comprises mutations Q347R, D399V and F405T, and the Fc domain attached to the scFv comprises matching mutations K360E and K409W for forming heterodimers.
[0041] Figure 2A is the interaction plot of the average size measured by dynamic light scattering (DLS) after 3 weeks of incubation at 50°C. Figure 2B is an interaction plot of average size measured by DLS after 3 weeks of incubation at 2-8°C.
[0042] Figure 3Ais the interaction plot of monomer size measured by DLS after 3 weeks of incubation at 50°C. Figure 3B is the interaction plot of monomer size measured by DLS after 3 weeks of incubation at 2-8°C.
[0043] Figure 4A Interaction plots are % of the main species determined by size exclusion chromatography (SEC) after 3 weeks incubation at 50°C. Figure 4B Interaction plots are % of the major species determined by SEC after 3 weeks incubation at 2-8°C.
[0044] Figure 5A Interaction plot of the percentage of high molecular weight species (% HMW) determined by SEC after 3 weeks of incubation at 50°C. Figure 5B is the interaction plot of % HMW determined by SEC after 3 weeks incubation at 2-8°C.
[0045] Fig. 6A Interaction plot of the percentage of low molecular weight species (%LMW) determined by SEC after 3 weeks of incubation at 50°C. Figure 6B is an interaction plot of %LMW determined by SEC after 3 weeks incubation at 2-8°C.
[0046] Fig. 7A is the interaction graph of % acidic species determined by imaging capillary isoelectric focusing (icIEF) after 3 weeks of incubation at 50°C. Figure 7B Interaction plot of % basicity determined by icIEF for sucrose alone after 3 weeks incubation at 4-8°C.
[0047] Fig. 8A is a graph of the % interactions of the main substances determined by icIEF after 3 weeks of incubation at 50°C. Figures 8B-8D is at 4°C and pH 5.5 ( Figure 8B )、pH 6.0( Figure 8C ) and pH 6.5 ( Fig.8D ) after 3 weeks of incubation with icIEF.
[0048] Fig.9A is the interaction graph of % basic substances determined by icIEF after 3 weeks of incubation at 50°C. Fig. 9B Interaction plot of % of basic substances determined by icIEF for sucrose alone after 3 weeks incubation at 2-8°C.
[0049] Fig. 10A Interaction plots are % purity determined by capillary electrophoresis (CE) after 3 weeks incubation at 50°C. Fig. 10B is an interaction plot of the % of impurities determined by CE after 3 weeks of incubation at 50°C.
[0050] Fig.11A is the % interaction plot of the main species determined by capillary electrophoresis (non-reduced) (CE(NR)) after 3 weeks of incubation at 50°C and pH 6.0. Fig. 11B is the interaction plot of % of the main species determined by CE (NR) after 3 weeks of incubation at 2-8°C and pH 6.0.
[0051] Fig. 12A is the interaction plot of % HMW determined by CE (NR) after 3 weeks of incubation at 50°C. Fig. 12B is the interaction plot of % HMW determined by CE (NR) after 3 weeks of incubation at 2-8°C.
[0052] Fig.13A is an interaction plot of %LMW determined by CE (NR) for sucrose only after 3 weeks of incubation at 50°C. Fig. 13B is an interaction plot of %LMW determined by CE (NR) for sucrose alone after 3 weeks of incubation at 2-8°C.
[0053] Figures 14A-14B is a schematic diagram of the clinical trial design. Fig.14A The trial design used for the dose-escalation phase is described. Fig. 14B The trial design for the efficacy expansion cohort phase is described. Abbreviations used in the figures include: DL = dose level; Combo PD-1 = combination therapy with pembrolizumab; PK = pharmacokinetics; PD = pharmacodynamics; Her2 HIGH = HER2 high expression of 3+ by immunohistochemistry; MBC HER2 2+ / 1+ = metastatic breast cancer with HER2 intermediate / low expression of 2+ / 1+ by immunohistochemistry; UBC 2L / 3L = 2nd / 3rd line treatment for urothelial bladder cancer. Detailed Description
[0055] definition
[0056] To facilitate understanding of the present invention, a number of terms and phrases are defined below.
[0057] As used herein, a reference without a specific number means "one or more" and includes the plural referent unless the context is inappropriate.
[0058] When used herein, the terms "Fab" and "scFv" refer to two different forms of protein fragments that each include an antigen binding site. The term "antigen binding site" refers to the part of an immunoglobulin molecule that participates in antigen binding. In human antibodies, the antigen binding site is formed by amino acid residues of the N-terminal variable ("V") region of the heavy ("H") chain and the light ("L") chain (which are also referred to as "VH" and "VL" respectively). The three highly divergent segments in the V region of the heavy and light chains are referred to as "hypervariable regions", which are inserted between the more conservative flanking segments referred to as "framework regions" or "FRs". Therefore, the term "FR" refers to the amino acid sequence that is naturally present between and adjacent to the hypervariable regions in immunoglobulins. In human antibody molecules, the three hypervariable regions of the light chain and the three hypervariable regions of the heavy chain are configured relative to each other in three-dimensional space to form an antigen binding surface. The antigen binding surface is complementary to the three-dimensional surface of the bound antigen, and the three hypervariable regions of each heavy chain and light chain are referred to as "complementarity determining regions" or "CDRs". In some animals, such as camels and cartilaginous fish, the antigen binding site is formed by a single antibody chain, providing a "single domain antibody". The antigen binding site can be present in an intact antibody, an antigen binding fragment of an antibody that retains the antigen binding surface, such as Fab, or a recombinant polypeptide, such as scFv, which uses a peptide linker to connect the heavy chain variable domain to the light chain variable domain in a single polypeptide. All amino acid positions in the heavy or light chain variable regions disclosed herein are numbered according to the Kabat numbering system.
[0059] The CDRs of an antigen binding site can be determined by the methods described in the following literature: Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977); Kabat et al., Sequences of protein of immunological interest, (1991); Chothia et al., J. Mol. Biol. 196: 901-917 (1987); MacCallum et al., J. Mol. Biol. 262: 732-745 (1996). CDRs determined under these definitions generally include overlaps or subsets of amino acid residues when compared to each other. In certain embodiments, the term "CDR" is a CDR as defined by MacCallum et al., J. Mol. Biol. 262: 732-745 (1996) and Martin A., Protein Sequence and Structure Analysis of Antibody Variable Domains, Antibody Engineering, Kontermann and Dubel, eds., Chapter 31, pp. 422-439, Springer-Verlag, Berlin (2001). In certain embodiments, the term "CDR" is a CDR as defined by Kabat et al., J. Biol. Chem. 252, 6609-6616 (1977), and Kabat et al., Sequences of protein of immunological interest, (1991). In certain embodiments, the heavy chain CDR and light chain CDR of an antibody are defined using different conventions. For example, in certain embodiments, the heavy chain CDRs are defined according to MacCallum (supra), and the light chain CDRs are defined according to Kabat (supra).CDRH1, CDRH2, and CDRH3 represent the CDRs of the heavy chain, and CDRL1, CDRL2, and CDRL3 represent the CDRs of the light chain.
[0060] As used herein, the term "pharmaceutical preparation" refers to the combination of an active agent with an inert or active carrier, rendering the composition particularly suitable for in vivo or ex vivo diagnostic or therapeutic use.
[0061] As used herein, the terms "subject" and "patient" refer to an organism to be treated by the methods and compositions described herein. These organisms preferably include, but are not limited to, mammals (e.g., murines, simians, equines, bovines, porcines, primates, canines, felines, etc.), and more preferably include humans.
[0062] As used in the present disclosure, the term "treat" and other grammatical equivalents include alleviating, relieving, ameliorating or preventing a disease, condition or symptom, preventing additional symptoms, ameliorating or preventing potential metabolic causes of symptoms, inhibiting a disease or condition such as arresting the development of a disease or condition, alleviating a disease or condition, causing regression of a disease or condition, alleviating a condition caused by a disease or condition, or stopping the symptoms of a disease or condition, and are intended to include prevention. The term also includes achieving a therapeutic benefit and / or a prophylactic benefit. A therapeutic benefit refers to the eradication or improvement of the underlying disorder being treated. In addition, a therapeutic benefit is achieved by the eradication or improvement of one or more physiological symptoms associated with the underlying disorder, such that an improvement is observed in the patient, although the patient may still be suffering from the underlying disorder.
[0063] The term "about" refers to any minimal variation in the concentration or amount of a pharmaceutical agent that does not alter the efficacy of the pharmaceutical agent in the preparation of a formulation and the treatment of a disease or disorder. In certain embodiments, the term "about" may include ±5%, ±10%, or ±15% of a specified value or data point.
[0064] In the present disclosure, ranges can be expressed as from "about" a specific value and / or to "about" another specific value. When such a range is expressed, another case includes from the specific value and / or to the specific value. Similarly, when a value is expressed as an approximation by using the antecedent "about", it should be understood that the specific value forms another case. It should also be understood that the endpoints of each of the ranges are important in both cases of being associated with and independent of the other endpoint. It should also be understood that multiple values are disclosed in the present disclosure, and each value is disclosed as "about" the specific value in addition to the value itself. It should also be understood that throughout the present application, data is provided in a variety of different formats, and the data represents the range of any combination of endpoints and starting points and the data points. For example, if a specific data point "10" and a specific data point "15" are disclosed, it should be understood that, in addition to between 10 and 15, it is also believed that greater than, greater than or equal to, less than, less than or equal to, and equal to 10 and 15 are also disclosed. It should also be understood that each unit between two specific units is also disclosed. For example, if 10 and 15 are disclosed, then 11, 12, 13, and 14 are also disclosed.
[0065] Throughout this specification, when compositions are described as having, including, or comprising specific components, or when processes and methods are described as having, including, or comprising specific steps, it is contemplated that there are additional compositions of the invention consisting essentially of, or consisting of, the recited components, and that there are additional processes and methods consistent with the invention consisting essentially of, or consisting of, the recited process steps.
[0066] Generally, compositions specifying percentages are by weight unless otherwise specified. In addition, if a variable is not accompanied by a definition, the preceding definition of the variable will prevail.
[0067] Multispecific binding proteins
[0068] The present disclosure provides a pharmaceutical preparation comprising a multispecific binding protein, wherein the multispecific binding protein has a scFv that binds to HER2, a Fab that binds to NKG2D, and an antibody Fc domain, wherein the ingredients in the preparation are optimized for the stability of the multispecific binding protein. Also provided is a dosage regimen for using the multispecific binding protein and the pharmaceutical preparation in the treatment of cancer, such as locally advanced or metastatic solid tumors. The multispecific binding protein is capable of binding to HER2 on cancer cells and NKG2D and CD16 on natural killer cells. This binding brings the cancer cells to the vicinity of natural killer cells, promoting direct and indirect destruction of the cancer cells by the natural killer cells.
[0069] The first component of the multispecific binding protein binds to cells expressing the NKG2D receptor, which cells may include but are not limited to NK cells, NKT cells, γδT cells and CD8 + αβT cells. After NKG2D binding, the multispecific binding protein can block natural ligands such as ULBP6 and MICA from binding to NKG2D and activating NK cells. The second component of the multispecific binding protein binds to cells expressing HER2, which may include but are not limited to cells of breast cancer, ovarian cancer, esophageal cancer, bladder cancer and gastric cancer, salivary duct cancer, lung adenocarcinoma and aggressive forms of uterine cancer such as uterine serous endometrial cancer. The third component of the multispecific binding protein is an antibody Fc domain, which binds to cells expressing CD16 such as NK cells, macrophages, neutrophils, eosinophils, mast cells and follicular dendritic cells.
[0070] The multispecific binding proteins described herein can take a variety of different formats. For example, one format involves a heterodimeric multispecific antibody ( Figure 1). The first immunoglobulin heavy chain includes a first antibody Fc sequence (hinge-CH2-CH3) fused to the heavy chain portion of Fab via a connector or an antibody hinge, the heavy chain portion of the Fab including a heavy chain variable domain and a CH1 domain. The immunoglobulin light chain includes a light chain portion of Fab, which includes a light chain variable domain and a light chain constant domain (CL), wherein the heavy chain and light chain portions of the Fab fragment are paired and bind to NKG2D. The second immunoglobulin heavy chain includes a second antibody Fc sequence (hinge-CH2-CH3) fused to a single chain variable fragment (scFv) via a connector or an antibody hinge, the scFv consisting of a heavy chain variable domain and a light chain variable domain that are paired and bind to HER2.
[0071] The individual components of the multispecific binding proteins are described in more detail below.
[0072] NKG2D binding site
[0073] After binding to the NKG2D receptor and CD16 receptor on natural killer cells and tumor-associated antigens on cancer cells, the multispecific binding protein can engage more than one NK activation receptor and can block the binding of natural ligands to NKG2D. In certain embodiments, the protein can excite NK cells in humans. In certain embodiments, the protein can excite NK cells in humans and other species such as rodents and cynomolgus monkeys.
[0074] Table 1 lists the peptide sequences of the heavy chain variable domain and the light chain variable domain that can bind to NKG2D in combination. In some embodiments, the heavy chain variable domain and the light chain variable domain are arranged in a Fab format. The binding affinity of these NKG2D-binding domains to NKG2D may vary, but they all activate human NK cells. Unless otherwise indicated, the CDR sequences provided in Table 1 are all determined under Kabat.
[0075] Table 1. Exemplary NKG2D binding sites
[0076]
[0077]
[0078]
[0079]
[0080]
[0081]
[0082]
[0083] In certain embodiments, the Fab comprises a heavy chain variable domain associated with SEQ ID NO: 94 and a light chain variable domain associated with SEQ ID NO: 98. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 94, and / or incorporate an amino acid sequence identical to CDR1 (SEQ ID NO: 95 or 168), CDR2 (SEQ ID NO: 96), and CDR3 (SEQ ID NO: 97 or 169) sequences of SEQ ID NO: 94. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:98, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO:100) and CDR3 (SEQ ID NO:101) sequences of SEQ ID NO:98.
[0084] In certain embodiments, the Fab comprises a heavy chain variable domain related to SEQ ID NO: 144 and a light chain variable domain related to SEQ ID NO: 98. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 144, and / or incorporate an amino acid sequence identical to CDR1 (SEQ ID NO: 95 or 168), CDR2 (SEQ ID NO: 96), and CDR3 (SEQ ID NO: 172 or 173) sequences of SEQ ID NO: 144. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:98, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO:100) and CDR3 (SEQ ID NO:101) sequences of SEQ ID NO:98.
[0085] In certain embodiments, the Fab comprises a heavy chain variable domain related to SEQ ID NO: 174 and a light chain variable domain related to SEQ ID NO: 98. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 174, and / or incorporate an amino acid sequence identical to CDR1 (SEQ ID NO: 95 or 168), CDR2 (SEQ ID NO: 96), and CDR3 (SEQ ID NO: 175 or 176) sequences of SEQ ID NO: 174. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:98, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO:100) and CDR3 (SEQ ID NO:101) sequences of SEQ ID NO:98.
[0086] In certain embodiments, the Fab comprises a heavy chain variable domain related to SEQ ID NO: 177 and a light chain variable domain related to SEQ ID NO: 98. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 177, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 95 or 168), CDR2 (SEQ ID NO: 96), and CDR3 (SEQ ID NO: 178 or 179) sequences of SEQ ID NO: 177. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:98, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO:100) and CDR3 (SEQ ID NO:101) sequences of SEQ ID NO:98.
[0087] In certain embodiments, the Fab comprises a heavy chain variable domain associated with SEQ ID NO: 180 and a light chain variable domain associated with SEQ ID NO: 98. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 180, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 95 or 168), CDR2 (SEQ ID NO: 96), and CDR3 (SEQ ID NO: 181 or 182) sequences of SEQ ID NO: 180. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:98, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO:100) and CDR3 (SEQ ID NO:101) sequences of SEQ ID NO:98.
[0088] In certain embodiments, the Fab comprises a heavy chain variable domain related to SEQ ID NO: 183 and a light chain variable domain related to SEQ ID NO: 98. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 183, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 95 or 168), CDR2 (SEQ ID NO: 96), and CDR3 (SEQ ID NO: 184 or 185) sequences of SEQ ID NO: 183. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:98, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO:100) and CDR3 (SEQ ID NO:101) sequences of SEQ ID NO:98.
[0089] In certain embodiments, the Fab comprises a heavy chain variable domain related to SEQ ID NO: 186 and a light chain variable domain related to SEQ ID NO: 98. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 186, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 95 or 168), CDR2 (SEQ ID NO: 96), and CDR3 (SEQ ID NO: 187 or 188) sequences of SEQ ID NO: 186. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:98, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:99), CDR2 (SEQ ID NO:100) and CDR3 (SEQ ID NO:101) sequences of SEQ ID NO:98.
[0090] In certain embodiments, the Fab comprises a heavy chain variable domain associated with SEQ ID NO: 86 and a light chain variable domain associated with SEQ ID NO: 90. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 86, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 87 or 166), CDR2 (SEQ ID NO: 88), and CDR3 (SEQ ID NO: 89 or 167) sequences of SEQ ID NO: 86. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:90, and / or incorporate amino acid sequences identical to CDR1 (SEQ ID NO:91), CDR2 (SEQ ID NO:92) and CDR3 (SEQ ID NO:93) sequences of SEQ ID NO:90.
[0091] In certain embodiments, the Fab comprises a heavy chain variable domain associated with SEQ ID NO: 102 and a light chain variable domain associated with SEQ ID NO: 106. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 102, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 71 or 162), CDR2 (SEQ ID NO: 72), and CDR3 (SEQ ID NO: 105 or 170) sequences of SEQ ID NO: 102. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 106, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 107), CDR2 (SEQ ID NO: 108) and CDR3 (SEQ ID NO: 109) sequences of SEQ ID NO: 106.
[0092] In certain embodiments, the Fab comprises a heavy chain variable domain associated with SEQ ID NO: 70 and a light chain variable domain associated with SEQ ID NO: 74. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 70, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 71 or 162), CDR2 (SEQ ID NO: 72), and CDR3 (SEQ ID NO: 73 or 163) sequences of SEQ ID NO: 70. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:74, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:75), CDR2 (SEQ ID NO:76) and CDR3 (SEQ ID NO:77) sequences of SEQ ID NO:74.
[0093] In certain embodiments, the Fab comprises a heavy chain variable domain associated with SEQ ID NO: 70 and a light chain variable domain associated with SEQ ID NO: 74. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 70, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 71 or 162), CDR2 (SEQ ID NO: 72), and CDR3 (SEQ ID NO: 73 or 163) sequences of SEQ ID NO: 70. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO:74, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO:75), CDR2 (SEQ ID NO:76) and CDR3 (SEQ ID NO:77) sequences of SEQ ID NO:74.
[0094] In certain embodiments, the Fab comprises a heavy chain variable domain associated with SEQ ID NO: 78 and a light chain variable domain associated with SEQ ID NO: 82. For example, the heavy chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 78, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 79 or 164), CDR2 (SEQ ID NO: 80), and CDR3 (SEQ ID NO: 81 or 165) sequences of SEQ ID NO: 78. Similarly, the light chain variable domain of the Fab can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100%) identical to SEQ ID NO: 82, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 75), CDR2 (SEQ ID NO: 76) and CDR3 (SEQ ID NO: 77) sequences of SEQ ID NO: 82.
[0095] The multispecific binding protein can bind to cells expressing NKG2D, including but not limited to NK cells, γδ T cells, and CD8 +αβ T cells. After binding to NKG2D, the multispecific binding protein can block natural ligands such as ULBP6 and MICA from binding to NKG2D and activating NK cells.
[0096] In certain embodiments, the Fab or multispecific binding protein is expressed as D 2nM to 120nM, for example, 2nM to 110nM, 2nM to 100nM, 2nM to 90nM, 2nM to 80nM, 2nM to 70nM, 2nM to 60nM, 2nM to 50nM, 2nM to 40nM, 2nM to 30nM, 2nM to 20nM, 2nM to 10nM, about 15nM, about 14nM, about 13nM, about 12nM, about 11nM, about 10nM, about 9nM, about 8nM, about 7nM, about 6nM, about 5nM, about 4.5nM, about 4nM, about 3.5nM, about 3nM, about 2.5nM, about 2nM, about 1.5 nM, about 1 nM, about 0.5 nM to about 1 nM, about 1 nM to about 2 nM, about 2 nM to 3 nM, about 3 nM to 4 nM, about 4 nM to about 5 nM, about 5 nM to about 6 nM, about 6 nM to about 7 nM, about 7 nM to about 8 nM, about 8 nM to about 9 nM, about 9 nM to about 10 nM, about 1 nM to about 10 nM, about 2 nM to about 10 nM, about 3 nM to about 10 nM, about 4 nM to about 10 nM, about 5 nM to about 10 nM, about 6 nM to about 10 nM, about 7 nM to about 10 nM, or about 8 nM to about 10 nM binds to NKG2D with an affinity of 1.5 nM, about 1 nM, about 0.5 nM to about 1 nM, about 1 nM to about 2 nM, about 2 nM to about 10 nM, about 3 nM to about 10 nM, about 4 nM to about 10 nM, about 5 nM to about 10 nM, about 6 nM to about 10 nM, about 7 nM to about 10 nM, or about 8 nM to about 10 nM.
[0097] In certain embodiments, the Fab has a K of 2 nM to 120 nM when measured by surface plasmon resonance. D In certain embodiments, the multispecific binding protein has a K of 2 nM to 120 nM when measured by surface plasmon resonance. D In certain embodiments, the Fab binds to NKG2D with a K of 10 nM to 62 nM when measured by surface plasmon resonance. D In certain embodiments, the multispecific binding protein has a K of 10 nM to 62 nM when measured by surface plasmon resonance. D Binds to NKG2D.
[0098] In certain embodiments, the Fab is linked to an antibody Fc sequence. In certain embodiments, the heavy chain portion of the Fab is linked to the N-terminus of the antibody Fc sequence.
[0099] HER2 binding site
[0100] The HER2 binding site of the multispecific binding protein disclosed herein comprises a heavy chain variable domain and a light chain variable domain fused together to form an scFv. Table 2 lists the peptide sequences of the heavy chain variable domain and the light chain variable domain that can bind to HER2 in combination.
[0101] Table 2. Exemplary HER2 binding sites
[0102]
[0103]
[0104] Alternatively, novel antigen binding sites that bind to HER2 can be identified by screening for binding to the amino acid sequence defined by SEQ ID NO: 138 or a mature extracellular fragment thereof.
[0105] MELAALCRWGLLLALLPPGAASTQVCTGTDMKLRLPASPETHLDMLRHLYQGCQVVQGNLELTYLPTN
[0106] ASLSFLQDIQEVQGYVLIAHNQVRQVPLQRLRRIVRGTQLFEDNYALAVLDNGDPLNNTTPVTGASPGGL
[0107] RELQLRSLTEILKGGVLIQRNPQLCYQDTILWKDIFHKNNQLALTLIDTNRSRACHPCSPMCKGSRCWGE
[0108] SSEDCQSLTRTVCAGGCARCKGPLPTDCCHEQCAAGCTGPKHSDCLACLHFNHSGICELHCPALVTYNT
[0109] DTFESMPNPEGRYTFGASCVTACPYNYLSTDVGSCTLVCPLHNQEVTAEDGTQRCEKCSKPCARVCYGL
[0110] GMEHLREVRAVTSANIQEFAGCKKIFGSLAFLPESFDGDPASNTAPLQPEQLQVFETLEEITGYLYISAWP
[0111] DSLPDLSVFQNLQVIRGRILHNGAYSLTLQGLGISWLGLRSLRELGSGLALIHHNTHLCFVHTVPWDQLF
[0112] RNPHQALLHTANRPEDECVGEGLACHQLCARGHCWGPGPTQCVNCSQFLRGQECVEECRVLQGLPREY
[0113] VNARHCLPCHPECQPQNGSVTCFGPEADQCVACAHYKDPPFCVARCPSGVKPDLSYMPIWKFPDEEGA
[0114] CQPCPINCTHSCVDLDDKGCPAEQRASPLTSIISAVVGILLVVVLGVVFGILIKRRQQKIRKYTMRRLLQE
[0115] TELVEPLTPSGAMPNQAQMRILKETELRKVKVLGSGAFGTVYKGIWIPDGENVKIPVAIKVLRENTSPKA
[0116] NKEILDEAYVMAGVGSPYVSRLLGICLTSTVQLVTQLMPYGCLLDHVRENRGRLGSQDLLNWCMQIAK
[0117] GMSYLEDVRLVHRDLAARNVLVKSPNHVKITDFGLARLLDIDETEYHADGGKVPIKWMALESILRRRFT
[0118] HQSDVWSYGVTVWELMTFGAKPYDGIPAREIPDLLEKGERLPQPPICTIDVYMIMVKCWMIDSECRPRF
[0119] RELVSEFSRMARDPQRFVVIQNEDLGPASPLDSTFYRSLLEDDDMGDLVDAEEYLVPQQGFFCPDPAPG
[0120] AGGMVHHRHRSSSTRSGGGDLTLGLEPSEEEAPRSPLAPSEGAGSDVFDGDLGMGAAKGLQSLPTHDPS
[0121] PLQRYSEDPTVPLPSETDGYVAPLTCSPQPEYVNQPDVRPQPPSPREGPLPAARPAGATLERPKTLSPGKN
[0122] GVVKDVFAFGGAVENPEYLTPQGGAAPQPHPPPAFSPAFDNLYYWDQDPPERGAPPSTFKGTPTAENPEYLGLDVPV(SEQ ID NO: 138)
[0123] In certain embodiments, the scFv comprises a heavy chain variable domain associated with SEQ ID NO: 195 and a light chain variable domain associated with SEQ ID NO: 196. For example, the heavy chain variable domain of the scFv can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 195, and / or incorporate an amino acid sequence identical to the CDR1 (SEQ ID NO: 115), CDR2 (SEQ ID NO: 116), and CDR3 (SEQ ID NO: 117) sequences of SEQ ID NO: 195. Likewise, the light chain variable domain of the scFv can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 196, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 119), CDR2 (SEQ ID NO: 120), and CDR3 (SEQ ID NO: 121) sequences of SEQ ID NO: 196. In certain embodiments, the scFv comprises the amino acid sequence of SEQ ID NO: 139.
[0124] In certain embodiments, the scFv comprises a heavy chain variable domain associated with SEQ ID NO: 197 and a light chain variable domain associated with SEQ ID NO: 198. For example, the heavy chain variable domain of the scFv can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 197, and / or incorporate amino acid sequences identical to CDR1 (SEQ ID NO: 123), CDR2 (SEQ ID NO: 124), and CDR3 (SEQ ID NO: 125) sequences of SEQ ID NO: 197. Likewise, the light chain variable domain of the scFv can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 198, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 127), CDR2 (SEQ ID NO: 128), and CDR3 (SEQ ID NO: 129) sequences of SEQ ID NO: 198. In certain embodiments, the scFv comprises the amino acid sequence of SEQ ID NO: 189.
[0125] In certain embodiments, the scFv comprises a heavy chain variable domain associated with SEQ ID NO: 199 and a light chain variable domain associated with SEQ ID NO: 200. For example, the heavy chain variable domain of the scFv can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 199, and / or incorporate amino acid sequences identical to CDR1 (SEQ ID NO: 131), CDR2 (SEQ ID NO: 132), and CDR3 (SEQ ID NO: 133) sequences of SEQ ID NO: 199. Likewise, the light chain variable domain of the scFv can be at least 90% (e.g., 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100%) identical to SEQ ID NO: 200, and / or incorporate amino acid sequences identical to the CDR1 (SEQ ID NO: 135), CDR2 (SEQ ID NO: 136), and CDR3 (SEQ ID NO: 137) sequences of SEQ ID NO: 200. In certain embodiments, the scFv comprises the amino acid sequence of SEQ ID NO: 171.
[0126] The above scFv includes a heavy chain variable domain and a light chain variable domain. In certain embodiments, the heavy chain variable domain forms a disulfide bond with the light chain variable domain to enhance the stability of the scFv. For example, a disulfide bond can be formed between the C44 residue of the heavy chain variable domain and the C100 residue of the light chain variable domain, and the amino acid positions are numbered under Kabat.
[0127] The VH and VL of the scFv can be placed in various different directions. In some embodiments, the VL is placed at the N-terminus of the VH. In some embodiments, the VL is placed at the C-terminus of the VH.
[0128] The VH and VL of the scFv can be connected by a connector such as a peptide connector. In some embodiments, the peptide connector is a flexible connector. Regarding the amino acid composition of the connector, the peptide is selected to have properties that confer flexibility, do not interfere with the structure and function of other domains of the protein of the present invention, and resist protease cleavage. For example, glycine and serine residues generally provide protease resistance. In some embodiments, the VL is placed at the N-terminal of the VH and is connected to the VH by a connector.
[0129] The length of the connector (e.g., a flexible connector) can be "short", such as 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 amino acid residues, or "long", such as at least 13 amino acid residues. In certain embodiments, the length of the connector is 10-50, 10-40, 10-30, 10-25, 10-20, 15-50, 15-40, 15-30, 15-25, 15-20, 20-50, 20-40, 20-30 or 20-25 amino acid residues.
[0130] In certain embodiments, the linker comprises (GS) n (SEQ ID NO: 204), (GGS) n (SEQ ID NO: 205), (GGGS) n (SEQ ID NO: 151), (GGSG) n (SEQ ID NO: 153), (GGSGG) n (SEQ ID NO: 156) and (GGGGS) n(SEQ ID NO: 157) sequence or consists of said sequence, wherein n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20. In certain embodiments, the linker comprises or consists of an amino acid sequence selected from SEQ ID NO: 143, SEQ ID NO: 201, SEQ ID NO: 202, SEQ ID NO: 103, SEQ ID NO: 104, SEQ ID NO: 83, SEQ ID NO: 84, SEQ ID NO: 150, SEQ ID NO: 152 and SEQ ID NO: 154 listed in Table 3. In certain embodiments, the linker is a (G4S)4 (SEQ ID NO: 203) linker consisting of the sequence of SEQ ID NO: 143.
[0131] Table 3. Exemplary linkers
[0132]
[0133]
[0134] In a specific embodiment, the light chain variable domain is connected to the N-terminus of the heavy chain variable domain via a flexible linker, such as a (G4S)4 linker (SEQ ID NO: 203).
[0135] In certain embodiments, the scFv is connected to the antibody Fc sequence via a hinge sequence. In certain embodiments, the hinge comprises amino acids Ala-Ser. In certain other embodiments, the hinge comprises amino acids Ala-Ser and Thr-Lys-Gly. The hinge sequence can provide flexibility for binding to the target antigen and a balance between flexibility and optimal geometry.
[0136] Fc domain
[0137] The antibody Fc domain of the multispecific binding protein comprises a first antibody Fc sequence connected to the Fab and a second antibody Fc sequence connected to the scFv. The two antibody Fc sequences pair and form a dimer that binds to CD16.
[0138] In the antibody Fc domain, CD16 binding is mediated by the hinge region and CH2 domain. For example, in human IgG1, the interaction with CD16 is mainly focused on the amino acid residues Asp 265-Glu269, Asn 297-Thr 299, Ala327-Ile 332, Leu 234-Ser 239 and the sugar residue N-acetyl-D-glucosamine in the CH2 domain (see Sondermann et al., Nature, 406(6793): 267-273). Based on the known domain, mutations can be selected to increase or decrease the binding affinity with CD16, for example, by using a phage display library or a yeast surface cDNA library, or mutations can be designed based on the known three-dimensional structure of the interaction.
[0139] The assembling of heterodimeric antibody heavy chains can be realized by expressing two different antibody heavy chain sequences in the same cell, which may result in the assembling of homodimers of every kind of antibody heavy chains and the assembling of heterodimers. The preference assembling of promoting heterodimers can be realized by incorporating different mutations into the CH3 domain of every kind of antibody heavy chain constant region, as shown in US13 / 494870, US16 / 028850, US11 / 533709, US12 / 875015, US13 / 289934, US14 / 773418, US12 / 811207, US13 / 866756, US14 / 647480 and US14 / 830336. For example, it is possible to make mutations in the CH3 domain on the basis of human IgG1 by incorporating different pairs of amino acid replacements into the first polypeptide and the second polypeptide, to allow these two chains to selectively heterodimerize each other. The position of the amino acid replacement shown below is all numbered according to the EU index in Kabat.
[0140] In one case, the amino acid substitution in the first polypeptide replaces the original amino acid with a larger amino acid selected from arginine (R), phenylalanine (F), tyrosine (Y) or tryptophan (W), and at least one amino acid substitution in the second polypeptide replaces the original amino acid with a smaller amino acid selected from alanine (A), serine (S), threonine (T) or valine (V), so that the larger amino acid substitution (protrusion) fits into the surface of the smaller amino acid substitution (hole). For example, one polypeptide can include a T366W substitution, and another polypeptide can include three substitutions, including T366S, L368A and Y407V.
[0141] The antibody heavy chain variable domain of the present invention can be optionally coupled to an amino acid sequence with at least 90% identity to an antibody constant region, such as an IgG constant region including hinge, CH2 and CH3 domains and containing or not containing a CH1 domain. In certain embodiments, the amino acid sequence of the constant region is at least 90% identical to a human antibody constant region, such as a human IgG1 constant region, an IgG2 constant region, an IgG3 constant region, or an IgG4 constant region. In certain other embodiments, the amino acid sequence of the constant region is at least 90% identical to an antibody constant region from another mammal, such as a rabbit, dog, cat, mouse, or horse. One or more mutations may be incorporated into the constant region compared to a human IgG1 constant region, for example at Q347, Y349, L351, S354, E356, E357, K360, Q362, S364, T366, L368, K370, N390, K392, T394, D399, S400, D401, F405, Y407, K409, T411 and / or K439. Exemplary substitutions include, for example, Q347E, Q347R, Y349S, Y349K, Y349T, Y349D, Y349E, Y349C, T350V, L351K, L351D, L351Y, S354C, E356K, E357Q, E357L, E357W, K360E, K360W, Q362E, S364K, S364E, S364H, S364D, T366V, T366I, T366L, T366M, T366K, T366W, T366 92E, K392L, K392M, K392V, K392F, K392D, K392E, T394F, T394W, D399R, D399K, D399V, S400K, S400R, D401K, F405A, F405T, Y407A, Y407I, Y407V, K409F, K409W, K409D, T411D, T411E, K439D and K439E. All amino acid positions in the Fc domain or hinge region disclosed herein are numbered according to the EU numbering system.
[0142] In certain embodiments, mutations that can be incorporated into the CH1 of the human IgG1 constant region can be at amino acids V125, F126, P127, T135, T139, A140, F170, P171, and / or V173. In certain embodiments, mutations that can be incorporated into the CK of the human IgG1 constant region can be at amino acids E123, F116, S176, V163, S174, and / or T164.
[0143] Amino acid substitutions may be selected from the groups of substitutions shown in Table 4 below.
[0144] Table 4. Exemplary Fc substitutions that promote heterodimerization
[0145] The first polypeptide The second polypeptide Group 1 S364E / F405A Y349K / T394F Group 2 S364H / D401K Y349T / T411E Group 3 S364H / T394F Y349T / F405A Group 4 S364E / T394F Y349K / F405A Group 5 S364E / T411E Y349K / D401K Group 6 S364D / T394F Y349K / F405A Group 7 S364H / F405A Y349T / T394F Group 8 S364K / E357Q L368D / K370S Group 9 L368D / K370S S364K Group 10 L368E / K370S S364K Group 11 K360E / Q362E D401K Group 12 L368D / K370S S364K / E357L Group 13 K370S S364K / E357Q Group 14 F405L K409R Group 15 K409R F405L
[0146] Alternatively, amino acid substitutions may be selected from the groups of substitutions shown in Table 5 below.
[0147] Table 5. Exemplary Fc substitutions that promote heterodimerization
[0148] The first polypeptide The second polypeptide Group 1 K409W D399V / F405T Group 2 Y349S E357W Group 3 K360E Q347R Group 4 K360E / K409W Q347R / D399V / F405T Group 5 Q347E / K360E / K409W Q347R / D399V / F405T Group 6 Y349S / K409W E357W / D399V / F405T
[0149] Alternatively, amino acid substitutions may be selected from the group of substitutions shown in Table 6 below.
[0150] Table 6. Exemplary Fc substitutions that promote heterodimerization
[0151] The first polypeptide The second polypeptide Group 1 T366K / L351K L351D / L368E Group 2 T366K / L351K L351D / Y349E Group 3 T366K / L351K L351D / Y349D Group 4 T366K / L351K L351D / Y349E / L368E Group 5 T366K / L351K L351D / Y349D / L368E Group 6 E356K / D399K K392D / K409D
[0152] Alternatively, at least one amino acid substitution in each polypeptide chain may be selected from Table 7.
[0153] Table 7. Exemplary Fc substitutions for facilitation
[0154]
[0155] Alternatively, at least one amino acid substitution may be selected from the group of substitutions in Table 8 below, wherein the positions noted in the first polypeptide column are replaced by any known negatively charged amino acid, and the positions noted in the second polypeptide column are replaced by any known positively charged amino acid.
[0156] Table 8. Exemplary Fc positions for substitution
[0157] The first polypeptide The second polypeptide K392, K370, K409 or K439 D399, E356 or E357
[0158] Alternatively, at least one amino acid substitution can be selected from the group of substitutions in Table 9 below, wherein the positions noted in the first polypeptide column are replaced by any known positively charged amino acid, and the positions noted in the second polypeptide column are replaced by any known negatively charged amino acid.
[0159] Table 9. Exemplary Fc positions for substitution
[0160] The first polypeptide The second polypeptide D399, E356 or E357 K409, K439, K370 or K392
[0161] Alternatively, amino acid substitutions may be selected from the group of substitutions in Table 10 below.
[0162] Table 10. Exemplary Fc substitutions that promote heterodimerization
[0163] The first polypeptide The second polypeptide T350V, L351Y, F405A and Y407V T350V, T366L, K392L and T394W
[0164] When selecting Fc replacement, the skilled person will recognize that the first polypeptide and the second polypeptide in Tables 4-10 may correspond to the first antibody Fc sequence and the second antibody Fc sequence, respectively. Alternatively, the first polypeptide and the second polypeptide in Tables 4-10 may correspond to the second antibody Fc sequence and the first antibody Fc sequence, respectively.
[0165] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at position T366, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from T366, L368 and Y407.
[0166] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from T366, L368 and Y407, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at position T366.
[0167] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of E357, K360, Q362, S364, L368, K370, T394, D401, F405 and T411, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Y349, E357, S364, L368, K370, T394, D401, F405 and T411.
[0168] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of Y349, E357, S364, L368, K370, T394, D401, F405 and T411, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of an IgG1 constant region at one or more positions selected from the group consisting of E357, K360, Q362, S364, L368, K370, T394, D401, F405 and T411.
[0169] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from L351, D399, S400 and Y407, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from T366, N390, K392, K409 and T411.
[0170] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from T366, N390, K392, K409 and T411, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from L351, D399, S400 and Y407.
[0171] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from Q347, Y349, K360 and K409, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from Q347, E357, D399 and F405.
[0172] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from Q347, E357, D399 and F405, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from Y349, K360, Q347 and K409.
[0173] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from K370, K392, K409 and K439, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from D356, E357 and D399.
[0174] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from D356, E357 and D399, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from K370, K392, K409 and K439.
[0175] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from L351, E356, T366 and D399, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from Y349, L351, L368, K392 and K409.
[0176] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from Y349, L351, L368, K392 and K409, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region at one or more positions selected from L351, E356, T366 and D399.
[0177] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region in the substitutions of K360E and K409W, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region in the substitutions of Q347R, D399V and F405T.
[0178] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region by Q347R, D399V and F405T substitutions, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region by K360E and K409W substitutions.
[0179] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region in the substitution of T366W, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region in the substitutions of T366S, T368A and Y407V.
[0180] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region in the substitutions of T366S, T368A and Y407V, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region in the substitution of T366W.
[0181] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from that of the IgG1 constant region by substitutions of T350V, L351Y, F405A and Y407V, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from that of the IgG1 constant region by substitutions of T350V, T366L, K392L and T394W.
[0182] In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from that of the IgG1 constant region by substitutions of T350V, T366L, K392L, and T394W, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from that of the IgG1 constant region by substitutions of T350V, L351Y, F405A, and Y407V.
[0183] Alternatively or additionally, the structural stability of the heteromultimeric protein can be improved by introducing S354C on either the first or second polypeptide chain and Y349C on the opposite polypeptide chain, the mutations forming an artificial disulfide bond within the interface of the two polypeptides. In certain embodiments, the amino acid sequence of one polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region by the S354C substitution, and wherein the amino acid sequence of the other polypeptide chain of the antibody constant region differs from the amino acid sequence of the IgG1 constant region by the Y349C substitution.
[0184] When selecting Fc replacement, the skilled person will recognize that the "one polypeptide chain" and the "other polypeptide chain" of the above antibody constant region may correspond to the first antibody Fc sequence and the second antibody Fc sequence, respectively. Alternatively, the "one polypeptide chain" and the "other polypeptide chain" of the above antibody constant region may correspond to the second antibody Fc sequence and the first antibody Fc sequence, respectively.
[0185] Exemplary Multispecific Binding Proteins
[0186] Listed below are examples of TriNKETs comprising scFvs that bind to HER2 and Fabs that bind to NKG2D, each connected to an antibody constant region, wherein the antibody constant region includes a mutation that enables heterodimerization of two Fc chains. The scFv comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) derived from an anti-HER2 antibody (e.g., trastuzumab), and further comprises replacement of the amino acid residues at position 100 of VL and position 44 of VH by Cys, thereby promoting the formation of a disulfide bond between the VH and VL of the scFv. The VL is connected to the N-terminus of the VH via a (G4S)4 connector (SEQ ID NO: 203), and the VH is connected to the N-terminus of the Fc via an Ala-Ser connector. The Ala-Ser connector is included at the elbow hinge region sequence to achieve a balance between flexibility and optimal geometry. In certain embodiments, the additional sequence Thr-Lys-Gly can be added to the N-terminus or C-terminus of the Ala-Ser sequence at the hinge.When used herein to describe these exemplary TriNKETs, the Fc includes the antibody hinge, CH2, and CH3.
[0187] Thus, each TriNKET described below comprises the following three polypeptide chains:
[0188] Chain A, which comprises from N-terminus to C-terminus: VH, CH1 and Fc of Fab that binds to NKG2D;
[0189] Chain B, which comprises, from N-terminus to C-terminus: VL of a scFv that binds to HER2, a (G4S)4 linker (SEQ ID NO: 203), VH of a scFv that binds to HER2, an Ala-Ser linker, and Fc; and
[0190] Chain C comprises, from N-terminus to C-terminus: VL of the Fab that binds to NKG2D, and CL.
[0191] The amino acid sequences of the exemplary TriNKETs are summarized in Table 11.
[0192] In certain embodiments, the multispecific binding protein of the present disclosure comprises a first polypeptide chain, a second polypeptide chain, and a third polypeptide chain, wherein the first, second, and third polypeptide chains respectively comprise the amino acid sequences of chain A, chain B, and chain C of TriNKET disclosed in Table 11. In certain embodiments, the first, second, and third polypeptide chains respectively consist of the amino acid sequences of chain A, chain B, and chain C of TriNKET disclosed in Table 11.
[0193] In an exemplary embodiment, the Fc domain of the Fab fragment connected to NKG2D comprises mutations Q347R, D399V and F405T, and the Fc domain connected to the HER2 scFv comprises matching mutations K360E and K409W for forming heterodimers. In another exemplary embodiment, the Fc domain of the Fab fragment connected to NKG2D comprises knob mutations T366S, L368A and Y407V, and the Fc domain connected to the scFv that binds HER2 comprises the "hole" mutation T366W. In an exemplary embodiment, the Fc domain of the Fab fragment connected to NKG2D comprises an S354C substitution in the CH3 domain, which forms a disulfide bond with the Y349C substitution on the Fc of the scFv that is connected to the HER2 binding.
[0194]
[0195] Specific TriNKETs and their polypeptide chains are described in more detail below. In the amino acid sequence, (G4S)4 (SEQ ID NO: 203) and the Ala-Ser linker are underlined bold; the Cys residues that form disulfide bonds in the scFv are underlined bold-italic; the Fc heterodimerization mutations are underlined bold; and the CDR sequences under Kabat are underlined.
[0196] For example, the TriNKET of the present disclosure is A49-F3'-TriNKET-trastuzumab. A49-F3'-TriNKET-trastuzumab includes: a single chain variable fragment (scFv) (SEQ ID NO: 139) derived from trastuzumab that binds HER2, which is connected to the Fc domain via a hinge comprising Ala-Ser; and a Fab fragment that binds NKG2D derived from A49, which includes a heavy chain portion comprising a heavy chain variable domain (SEQ ID NO: 94) and a CH1 domain, and a light chain portion comprising a light chain variable domain (SEQ ID NO: 98) and a light chain constant domain, wherein the heavy chain variable domain is connected to the CH1 domain, and the CH1 domain is connected to the Fc domain. A49-F3'-TriNKET-trastuzumab includes three polypeptides having the sequences of SEQ ID NO: 140, SEQ ID NO: 141, and SEQ ID NO: 142.
[0197] SEQ ID NO: 140 represents the complete sequence of a HER2-binding scFv (scFv-Fc) connected to an Fc domain via a hinge comprising Ala-Ser. The Fc domain connected to the scFv includes Q347R, D399V, and F405T substitutions for heterodimerization and an S354C substitution for disulfide bond formation with the Y349C substitution in SEQ ID NO: 141 as described below. The scFv (SEQ ID NO: 139) includes the heavy chain variable domain of trastuzumab connected to the N-terminus of the light chain variable domain of trastuzumab via a (G4S)4 linker (SEQ ID NO: 203), the scFv being represented as VL-(G4S)4-VH ("(G4S)4" is represented by SEQ ID NO: 203 or SEQ ID NO: 143). The heavy and light chain variable domains of the scFv are also linked by a disulfide bond between C100 of VL and C44 of VH as a result of Q100C and G44C substitutions in VL and VH, respectively.
[0198] Trastuzumab scFv
[0199]
[0200] Trastuzumab scFv-Fc (RVT)
[0201]
[0202] SEQ ID NO: 141 represents the heavy chain portion of the Fab fragment connected to the Fc domain, the heavy chain portion comprising the heavy chain variable domain of the NKG2D binding site (SEQ ID NO: 94) and the CH1 domain. The Fc domain in SEQ ID NO: 141 includes a Y349C substitution in the CH3 domain, which forms a disulfide bond with the S354C substitution on the Fc (SEQ ID NO: 140) connected to the HER2-binding scFv. In SEQ ID NO: 141, the Fc domain also includes K360E and K409W substitutions for heterodimerization with the Fc in SEQ ID NO: 140.
[0203] A49 VH
[0204] EVQLVESGGGLVKPGGSLRLSCAASGFTFS SYSMN WVRQAPGKGLEWVS SISSSSSYIYYADSVKG RFTISRDNAKNSLYLQMNSLRAEDTAVYYCAR GAPMGAAAGWFDP WGQGTLVTVSS (SEQ ID NO: 94)
[0205] A49 VH-CH1-Fc(EW)
[0206]
[0207] SEQ ID NO: 142 represents the light chain portion of the Fab fragment, which comprises the light chain variable domain of the NKG2D binding site (SEQ ID NO: 98) and the light chain constant domain.
[0208] A49 VL
[0209] DIQMTQSPSSVSASVGDRVTITC RASQGISSWLA WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQGVSFPRTF GGGTKVEIK (SEQ ID NO: 98)
[0210] A49 VL-LC
[0211] DIQMTQSPSSVSASVGDRVTITCRASQGISSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGVSFPRTFGGGTKVEIK RTVAAPSPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ ID NO:142)
[0212] Another TriNKET disclosed herein is A49MI-F3'-TriNKET-trastuzumab. A49MI-F3'-TriNKET-trastuzumab comprises the same HER2-binding scFv (SEQ ID NO: 139) as in A49-F3'-TriNKET-trastuzumab connected to the Fc domain via a hinge comprising Ala-Ser; and a Fab fragment derived from A49MI that binds NKG2D, comprising a heavy chain portion comprising a heavy chain variable domain (SEQ ID NO: 144) and a CH1 domain, and a light chain portion comprising a light chain variable domain (SEQ ID NO: 98) and a light chain constant domain, wherein the heavy chain variable domain is connected to the CH1 domain, and the CH1 domain is connected to the Fc domain. A49MI-F3'-TriNKET-Trastuzumab includes three polypeptides having the sequences of SEQ ID NO: 140 (same as in A49-F3'-TriNKET-Trastuzumab), SEQ ID NO: 145, and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-Trastuzumab).
[0213] SEQ ID NO: 145 represents the heavy chain portion of the Fab fragment connected to the Fc domain, the heavy chain portion comprising the heavy chain variable domain of the NKG2D binding site (SEQ ID NO: 144) and the CH1 domain. In SEQ ID NO: 144, the methionine in the CDR3 of SEQ ID NO: 94 has been replaced by isoleucine (M→I substitution; shown in the third bracket [] in SEQ ID NO: 144 and SEQ ID NO: 145). The Fc domain in SEQ ID NO: 145 includes a Y349C substitution in the CH3 domain, which forms a disulfide bond with the S354C substitution in the Fc (SEQ ID NO: 140) connected to the scFv that binds HER2. In SEQ ID NO: 145, the Fc domain also includes K360E and K409W substitutions.
[0214] A49MI VH
[0215]
[0216] A49MI VH-CH1-Fc(EW)
[0217]
[0218] Another TriNKET disclosed herein is A49-F3'-KiH-TriNKET-trastuzumab. KiH refers to knob-in-hole (KiH) Fc technology, which involves engineering the CH3 domain to create a "knob" or "hole" in each heavy chain that promotes heterodimerization. The concept behind the KiH Fc technology is to introduce a "knob" (e.g., T366W in EU numbering) into one CH3 domain (CH3A) by replacing small residues with larger residues. CH3A To accommodate the "knob", a complementary "hole" surface was created on the other CH3 domain (CH3B) by replacing the nearest neighboring residues to the knob with smaller residues (e.g. T366S / L368A / Y407V CH3BThe "hole" mutation was optimized by structure-guided phage library screening (Atwell S, Ridgway JB, Wells JA, Carter P., Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library, J. Mol. Biol. (1997) 270 (1): 26-35). X-ray crystal structure of a KiH Fc variant (Elliott JM, Ultsch M, Lee J, Tong R, Takeda K, Spiess C, et al., Antiparallel conformation of knob and hole aglycosylated half-antibody homodimers is mediated by a CH2-CH3 hydrophobic interaction, J. Mol. Biol. (2014) 426(9): 1947–57; Mimoto F, Kadono S, Katada H, Igawa T, Kamikawa T, Hattori K, Crystal structure of a novel asymmetrically engineered Fc variant with improved affinity for FcγRs) FcγRs), Mol. Immunol. (2014) 58(1):132–8) demonstrated that hydrophobic interactions driven by steric complementarity at the core interface between CH3 domains thermodynamically favor heterodimerization, whereas the knob-knob and hole-hole interfaces are unfavorable for homodimerization due to steric hindrance and disruption of favorable interactions, respectively.
[0219] A49-F3'-KiH-TriNKET-trastuzumab includes the same HER2-binding scFv (SEQ ID NO: 139) as in A49-F3'-TriNKET-trastuzumab, connected by a hinge comprising Ala-Ser to an Fc domain comprising "hole" substitutions of T366S, L368A and Y407V; and the same NKG2D-binding Fab fragment as in A49-F3'-TriNKET-trastuzumab, whose CH1 domain is connected to an Fc domain comprising a "knob" substitution of T366W. A49-F3'-KiH-TriNKET-trastuzumab includes three polypeptides having the sequences of SEQ ID NO: 146, SEQ ID NO: 147 and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-trastuzumab).
[0220] SEQ ID NO: 146 represents the complete sequence of a HER2-binding scFv (SEQ ID NO: 139) (scFv-Fc) connected to an Fc domain via a hinge comprising Ala-Ser. The Fc domain connected to the scFv includes T366S, L368A, and Y407V substitutions for heterodimerization and an S354C substitution for disulfide bond formation with the Y349C substitution in SEQ ID NO: 147 described below.
[0221] Trastuzumab scFv-Fc(KiH)
[0222]
[0223] SEQ ID NO: 147 represents the heavy chain portion of the Fab fragment connected to the Fc domain, the heavy chain portion comprising a heavy chain variable domain derived from the NKG2D binding site of A49 (SEQ ID NO: 94) and a CH1 domain. The Fc domain in SEQ ID NO: 147 comprises an S354C substitution, which forms a disulfide bond with a Y349C substitution in the CH3 domain of the Fc (SEQ ID NO: 146) connected to the HER2-binding scFv. In SEQ ID NO: 147, the Fc domain also comprises a T366W substitution.
[0224] A49 VH-CH1-Fc(KiH)
[0225]
[0226] Another TriNKET disclosed herein is A49MI-F3'-KiH-TriNKET-trastuzumab. A49MI-F3'-KiH-TriNKET-trastuzumab comprises the same HER2-binding scFv (SEQ ID NO: 139) as in A49-F3'-TriNKET-trastuzumab, connected by a hinge comprising Ala-Ser to an Fc domain comprising a "hole" replacement of T366S, L368A and Y407V; and the same NKG2D-binding Fab fragment as in A49MI-F3'-TriNKET-trastuzumab, whose CH1 domain is connected to an Fc domain comprising a "knob" replacement of T366W. A49MI-F3'-KiH-TriNKET-Trastuzumab includes three polypeptides having the sequences of SEQ ID NO: 146 (same as in A49-F3'-KiH-TriNKET-Trastuzumab), SEQ ID NO: 194 and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-Trastuzumab).
[0227] SEQ ID NO: 194 represents the heavy chain portion of the Fab fragment connected to the Fc domain, which comprises a heavy chain variable domain derived from the NKG2D binding site of A49MI (SEQ ID NO: 144) and a CH1 domain. The Fc domain in SEQ ID NO: 194 includes an S354C substitution, which forms a disulfide bond with a Y349C substitution in the CH3 domain in the Fc (SEQ ID NO: 146) connected to the scFv that binds HER2. In SEQ ID NO: 194, the Fc domain also includes a T366W substitution.
[0228] A49MI VH-CH1-Fc(KiH)
[0229]
[0230] Another exemplary TriNKET of the present disclosure is A44-F3'-TriNKET-trastuzumab. A44-F3'-TriNKET-trastuzumab includes the same HER2-binding scFv (SEQ ID NO: 139) as in A49-F3'-TriNKET-trastuzumab, which is connected to the Fc domain via a hinge comprising Ala-Ser; and a Fab fragment derived from A44 that binds NKG2D, which includes a heavy chain portion comprising a heavy chain variable domain (SEQ ID NO: 86) and a CH1 domain, and a light chain portion comprising a light chain variable domain (SEQ ID NO: 90) and a light chain constant domain, wherein the heavy chain variable domain is connected to the CH1 domain, and the CH1 domain is connected to the Fc domain. A44-F3'-TriNKET-Trastuzumab includes three polypeptides having the sequences of SEQ ID NO:140 (same as in A49-F3'-TriNKET-Trastuzumab), SEQ ID NO:155 and SEQ ID NO:149.
[0231] SEQ ID NO: 155 represents a heavy chain variable domain derived from the NKG2D binding site of A44 (SEQ ID NO: 86) connected to an Fc domain. The Fc domain in SEQ ID NO: 155 includes a Y349C substitution in the CH3 domain, which forms a disulfide bond with a S354C substitution on the Fc of a scFv that binds HER2 (SEQ ID NO: 140). In SEQ ID NO: 155, the Fc domain also includes K360E and K409W substitutions.
[0232] A44 VH
[0233] EVQLLESGGGLVQPGGSLRLSCAASGFTFS SYAMS WVRQAPGKGLEWVS AISGSGGSTYYADSVK G RFTISRDNSKNTLYLQMNSLRAEDTAVYYCAK DGGYYDSGAGDY WGQGTLVTVSS (SEQ ID NO: 86)
[0234] A44 VH-CH1-Fc(EW)
[0235]
[0236] SEQ ID NO: 149 represents the light chain portion of the Fab fragment, which comprises the light chain variable domain of the NKG2D binding site (SEQ ID NO: 90) and the light chain constant domain.
[0237] A44 VL
[0238] DIQMTQSPSSVSASVGDRVTITC RASQGIDSWLA WYQQKPGKAPKLLIY AASSLQS GVPSRFSGSGSGTDFTLTISSLQPEDFATYYC QQGVSYPRT FGGGTKVEIK (SEQ ID NO: 90)
[0239] A44 VL-CL
[0240] DIQMTQSPSSVSASVGDRVTITCRASQGIDSWLAWYQQKPGKAPKLLIYAASSLQSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQGVSYPRTFGGGTKVEIKRT VAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC(SEQ IDNO:149)
[0241] Another exemplary TriNKET of the present disclosure is A44-F3'-KiH-TriNKET-trastuzumab. A44-F3'-KiH-TriNKET-trastuzumab includes the same HER2-binding scFv (SEQ ID NO: 139) as in A49-F3'-TriNKET-trastuzumab, connected by a hinge comprising Ala-Ser to an Fc domain comprising "hole" substitutions of T366S, L368A and Y407V; and the same NKG2D-binding Fab fragment as in A44-F3'-TriNKET-trastuzumab, whose CH1 domain is connected to an Fc domain comprising a "knob" substitution of T366W. A44-F3'-KiH-TriNKET-Trastuzumab includes three polypeptides having the sequences of SEQ ID NO: 146 (same as in A49-F3'-KiH-TriNKET-Trastuzumab), SEQ ID NO: 148 and SEQ ID NO: 149 (same as in A44-F3'-TriNKET-Trastuzumab).
[0242] SEQ ID NO: 148 represents a heavy chain variable domain derived from the NKG2D binding site of A44 (SEQ ID NO: 86) connected to an Fc domain. The Fc domain in SEQ ID NO: 148 includes a Y349C substitution in the CH3 domain, which forms a disulfide bond with a S354C substitution on the Fc of the scFv that binds HER2 (SEQ ID NO: 146). In SEQ ID NO: 148, the Fc domain also includes a T366W substitution.
[0243] A44 VH-CH1-Fc(KiH)
[0244]
[0245] Another TriNKET of the present disclosure is A49-F3'-TriNKET-Pertuzumab. A49-F3'-TriNKET-Pertuzumab includes a HER2-binding scFv (SEQ ID NO: 189) derived from Pertuzumab connected to the Fc domain via a hinge comprising Ala-Ser, and the same Fab fragment binding to NKG2D as in A49-F3'-TriNKET-Trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes Q347R, D399V and F405T substitutions, and the Fc domain connected to the Fab fragment includes K360E and K409W substitutions. A49-F3'-TriNKET-Pertuzumab includes three polypeptides having the sequences of SEQ ID NO: 190, SEQ ID NO: 141 (same as in A49-F3'-TriNKET-Trastuzumab), and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-Trastuzumab).
[0246] SEQ ID NO: 190 represents the complete sequence of a HER2-binding scFv (scFv-Fc) connected to an Fc domain via a hinge comprising Ala-Ser. The Fc domain connected to the scFv includes Q347R, D399V, and F405T substitutions for heterodimerization and an S354C substitution for disulfide bond formation with the Y349C substitution in SEQ ID NO: 141 as described above. The scFv (SEQ ID NO: 189) includes the heavy chain variable domain of Pertuzumab connected to the N-terminus of the light chain variable domain of Pertuzumab via a (G4S)4 linker (SEQ ID NO: 203), the scFv being represented as VL-(G4S)4-VH ("(G4S)4" is represented by SEQ ID NO: 203 or SEQ ID NO: 143). The heavy and light chain variable domains of the scFv are also linked by a disulfide bond between C100 of VL and C44 of VH as a result of Q100C and G44C substitutions in VL and VH, respectively.
[0247] Pertuzumab scFv
[0248]
[0249] Pertuzumab scFv-Fc
[0250]
[0251] Another exemplary TriNKET of the present disclosure is A49MI-F3'-TriNKET-Pertuzumab. A49MI-F3'-TriNKET-Pertuzumab includes the same HER2-binding scFv (SEQ ID NO: 189) as in A49-F3'-TriNKET-Pertuzumab connected to the Fc domain via a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A49MI-F3'-TriNKET-Trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes Q347R, D399V and F405T substitutions, and the Fc domain connected to the Fab fragment includes K360E and K409W substitutions. A49MI-F3'-TriNKET-Pertuzumab includes three polypeptides having the sequences of SEQ ID NO: 190 (same as in A49-F3'-KiH-TriNKET-Pertuzumab), SEQ ID NO: 145 (same as in A49MI-F3'-TriNKET-Trastuzumab) and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-Trastuzumab).
[0252] Another exemplary TriNKET of the present disclosure is A49-F3'-KiH-TriNKET-Pertuzumab. A49-F3'-KiH-TriNKET-Pertuzumab includes the same HER2-binding scFv (SEQ ID NO: 189) as in A49-F3'-TriNKET-Pertuzumab connected to the Fc domain via a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A49-F3'-TriNKET-Trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes the "hole" substitutions of T366S, L368A, and Y407V, and the Fc domain connected to the Fab fragment includes the "knob" substitution of T366W. A49-F3'-KiH-TriNKET-Pertuzumab includes three polypeptides having the sequences of SEQ ID NO: 191, SEQ ID NO: 147 (same as in A49-F3'-KiH-TriNKET-Trastuzumab) and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-Trastuzumab).
[0253] SEQ ID NO: 191 represents the complete sequence of a HER2-binding scFv (SEQ ID NO: 189) (scFv-Fc) connected to an Fc domain via a hinge comprising Ala-Ser. The Fc domain connected to the scFv includes T366S, L368A and Y407V substitutions for heterodimerization and an S354C substitution for disulfide bond formation with the Y349C substitution in SEQ ID NO: 191 as described above.
[0254] Pertuzumab scFv-Fc(KiH)
[0255]
[0256] Another exemplary TriNKET of the present disclosure is A49MI-F3'-KiH-TriNKET-Pertuzumab. A49MI-F3'-KiH-TriNKET-Pertuzumab includes the same HER2-binding scFv (SEQ ID NO: 189) as in A49-F3'-TriNKET-Pertuzumab connected to the Fc domain via a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A49MI-F3'-TriNKET-Trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes the "hole" substitutions of T366S, L368A, and Y407V, and the Fc domain connected to the Fab fragment includes the "knob" substitution of T366W. A49MI-F3'-KiH-TriNKET-Pertuzumab includes three polypeptides having the sequences of SEQ ID NO: 191 (same as in A49-F3'-KiH-TriNKET-Pertuzumab), SEQ ID NO: 194 (same as in A49MI-F3'-KiH-TriNKET-Trastuzumab) and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-Trastuzumab).
[0257] Another exemplary TriNKET of the present disclosure is A44-F3'-TriNKET-Pertuzumab. A44-F3'-TriNKET-Pertuzumab includes the same HER2-binding scFv (SEQ ID NO: 189) as in A49-F3'-TriNKET-Pertuzumab connected to the Fc domain via a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A44-F3'-TriNKET-Trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes Q347R, D399V, and F405T substitutions, and the Fc domain connected to the Fab fragment includes K360E and K409W substitutions. A44-F3'-TriNKET-Pertuzumab includes three polypeptides having the sequences of SEQ ID NO: 190 (same as in A49-F3'-KiH-TriNKET-Pertuzumab), SEQ ID NO: 155 (same as in A44-F3'-TriNKET-Trastuzumab) and SEQ ID NO: 149 (same as in A44-F3'-TriNKET-Trastuzumab).
[0258] Another exemplary TriNKET of the present disclosure is A44-F3'-KiH-TriNKET-Pertuzumab. A44-F3'-KiH-TriNKET-Pertuzumab includes the same HER2-binding scFv (SEQ ID NO: 189) as in A49-F3'-TriNKET-Pertuzumab connected to the Fc domain via a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A44-F3'-TriNKET-Trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes the "hole" substitutions of T366S, L368A, and Y407V, and the Fc domain connected to the Fab fragment includes the "knob" substitution of T366W. A44-F3'-KiH-TriNKET-Pertuzumab includes three polypeptides having the sequences of SEQ ID NO: 191 (same as in A49-F3'-KiH-TriNKET-Pertuzumab), SEQ ID NO: 148 (same as in A44-F3'-KiH-TriNKET-Trastuzumab) and SEQ ID NO: 149 (same as in A44-F3'-TriNKET-Trastuzumab).
[0259] Another TriNKET disclosed herein is A49-F3'-TriNKET-MGAH22. A49-F3'-TriNKET-MGAH22 includes a HER2-binding scFv (SEQ ID NO: 171) derived from MGAH22 connected to an Fc domain via a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A49-F3'-TriNKET-trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes Q347R, D399V, and F405T substitutions, and the Fc domain connected to the Fab fragment includes K360E and K409W substitutions. A49-F3'-TriNKET-MGAH22 includes three polypeptides having the sequences of SEQ ID NO: 192, SEQ ID NO: 141 (same as in A49-F3'-TriNKET-trastuzumab), and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-trastuzumab).
[0260] SEQ ID NO: 192 represents the complete sequence of a HER2-binding scFv (scFv-Fc) connected to an Fc domain via a hinge comprising Ala-Ser. The Fc domain connected to the scFv includes Q347R, D399V, and F405T substitutions for heterodimerization, and an S354C substitution for disulfide bond formation with the Y349C substitution in SEQ ID NO: 141 as described above. The scFv (SEQ ID NO: 171) includes the heavy chain variable domain of Pertuzumab connected to the N-terminus of the light chain variable domain of Pertuzumab via a (G4S)4 linker (SEQ ID NO: 203), the scFv being represented as VL-(G4S)4-VH ("(G4S)4" is represented by SEQ ID NO: 203 or SEQ ID NO: 143). The heavy and light chain variable domains of the scFv are also linked by a disulfide bond between C100 of VL and C44 of VH as a result of G100C and G44C substitutions in VL and VH, respectively.
[0261] MGAH22 scFv
[0262]
[0263] MGAH22 scFv-Fc
[0264]
[0265] Another TriNKET disclosed herein is A49MI-F3'-TriNKET-MGAH22. A49MI-F3'-TriNKET-MGAH22 includes the same HER2-binding scFv (SEQ ID NO: 171) as in A49-F3'-TriNKET-MGAH22 connected to the Fc domain via a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A49MI-F3'-TriNKET-trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes Q347R, D399V and F405T substitutions, and the Fc domain connected to the Fab fragment includes K360E and K409W substitutions. A49MI-F3'-KiH-TriNKET-MGAH22 includes three polypeptides having the sequences of SEQ ID NO: 192 (same as in A49-F3'-TriNKET-MGAH22), SEQ ID NO: 145 (same as in A49MI-F3'-TriNKET-trastuzumab) and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-trastuzumab).
[0266] Another TriNKET of the present disclosure is A49-F3'-KiH-TriNKET-MGAH22. A49-F3'-KiH-TriNKET-MGAH22 includes the same HER2-binding scFv (SEQ ID NO: 171) as in A49-F3'-TriNKET-MGAH22 connected to the Fc domain by a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A49-F3'-TriNKET-trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes the "hole" substitutions of T366S, L368A and Y407V, and the Fc domain connected to the Fab fragment includes the "knob" substitution of T366W. A49-F3'-KiH-TriNKET-MGAH22 includes three polypeptides having the sequences of SEQ ID NO: 193, SEQ ID NO: 147 (identical to that in A49-F3'-KiH-TriNKET-trastuzumab), and SEQ ID NO: 142 (identical to that in A49-F3'-TriNKET-trastuzumab).
[0267] SEQ ID NO: 193 represents the complete sequence of a HER2-binding scFv (SEQ ID NO: 171) (scFv-Fc) connected to an Fc domain via a hinge comprising Ala-Ser. The Fc domain connected to the scFv includes T366S, L368A and Y407V substitutions for heterodimerization and an S354C substitution for disulfide bond formation with the Y349C substitution in SEQ ID NO: 147 as described above.
[0268] MGAH22 scFv-Fc(KiH)
[0269]
[0270] Another exemplary TriNKET of the present disclosure is A49MI-F3'-KiH-TriNKET-MGAH22. A49MI-F3'-KiH-TriNKET-MGAH22 includes the same HER2-binding scFv (SEQ ID NO: 171) as in A49-F3'-TriNKET-MGAH22 connected to the Fc domain by a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A49MI-F3'-TriNKET-trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes the "hole" substitutions of T366S, L368A and Y407V, and the Fc domain connected to the Fab fragment includes the "knob" substitution of T366W. A49MI-F3'-KiH-TriNKET-MGAH22 includes three polypeptides having the sequences of SEQ ID NO: 193 (same as in A49-F3'-KiH-TriNKET-MGAH22), SEQ ID NO: 194 (same as in A49MI-F3'-KiH-TriNKET-trastuzumab) and SEQ ID NO: 142 (same as in A49-F3'-TriNKET-trastuzumab).
[0271] Another exemplary TriNKET of the present disclosure is A44-F3'-TriNKET-MGAH22. A44-F3'-TriNKET-MGAH22 includes the same HER2-binding scFv (SEQ ID NO: 171) as in A49-F3'-TriNKET-MGAH22 connected to the Fc domain by a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A44-F3'-TriNKET-trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes Q347R, D399V and F405T substitutions, and the Fc domain connected to the Fab fragment includes K360E and K409W substitutions. A44-F3'-TriNKET-MGAH22 includes three polypeptides having the sequences of SEQ ID NO: 192 (same as in A49-F3'-TriNKET-MGAH22), SEQ ID NO: 155 (same as in A44-F3'-TriNKET-trastuzumab) and SEQ ID NO: 149 (same as in A44-F3'-TriNKET-trastuzumab).
[0272] Another exemplary TriNKET of the present disclosure is A44-F3'-KiH-TriNKET-MGAH22. A44-F3'-KiH-TriNKET-MGAH22 includes the same HER2-binding scFv (SEQ ID NO: 171) as in A49-F3'-TriNKET-MGAH22 connected to the Fc domain by a hinge comprising Ala-Ser; and the same NKG2D-binding Fab fragment as in A44-F3'-TriNKET-trastuzumab, with its CH1 domain connected to the Fc domain. The Fc domain connected to the scFv includes the "hole" substitutions of T366S, L368A and Y407V, and the Fc domain connected to the Fab fragment includes the "knob" substitution of T366W. A44-F3'-KiH-TriNKET-MGAH22 includes three polypeptides having the sequences of SEQ ID NO: 193 (same as in A49-F3'-KiH-TriNKET-MGAH22), SEQ ID NO: 148 (same as in A44-F3'-KiH-TriNKET-trastuzumab) and SEQ ID NO: 149 (same as in A44-F3'-TriNKET-trastuzumab).
[0273] In certain embodiments, a TriNKET of the present disclosure is identical to one of the exemplary TriNKETs described above comprising the EW-RVT Fc mutation, except that the Fc domain attached to the Fab fragment that binds NKG2D comprises substitutions of Q347R, D399V, and F405T, and the Fc domain attached to the scFv that binds HER2 comprises matching substitutions K360E and K409W, for forming heterodimers. In certain embodiments, a TriNKET of the present disclosure is identical to one of the exemplary TriNKETs described above comprising the KiH Fc mutation, except that the Fc domain attached to the Fab fragment that binds NKG2D comprises "hole" substitutions of T366S, L368A, and Y407V, and the Fc domain attached to the scFv that binds HER2 comprises a "knob" substitution of T366W, for forming heterodimers.
[0274] In certain embodiments, a TriNKET of the present disclosure is identical to one of the exemplary TriNKETs described above, except that the Fc domain attached to the Fab fragment that binds NKG2D comprises a S354C substitution in the CH3 domain, and the Fc domain attached to the scFv that binds HER2 comprises a matching Y349C substitution in the CH3 domain for forming a disulfide bond.
[0275] As described in International Application No. PCT / US2019 / 045561, the multispecific binding proteins disclosed herein effectively reduce tumor growth and kill cancer cells in in vitro assays and animal models. For example, A49-F3'-TriNKET-trastuzumab is superior to trastuzumab in inducing NK cell-mediated cytotoxicity against various human cancer cell lines such as 786-O cells expressing low levels of HER2 (HER2+), H661 cells expressing medium levels of HER2 (HER2++), and SkBr3 cells expressing high levels of HER2 (HER2+++). In addition, the multispecific binding protein does not significantly induce NK-mediated killing of healthy non-cancerous human cells (e.g., human cardiomyocytes).
[0276] Production of multispecific binding proteins
[0277] The above multispecific binding proteins can be manufactured using recombinant DNA techniques known to those skilled in the art. For example, a first nucleic acid sequence encoding the first immunoglobulin heavy chain can be cloned into a first expression vector; a second nucleic acid sequence encoding the second immunoglobulin heavy chain can be cloned into a second expression vector; a third nucleic acid sequence encoding the immunoglobulin light chain can be cloned into a third expression vector; and the first, second and third expression vectors can be stably transfected together into a host cell to produce the multimeric protein.
[0278] Those skilled in the art will recognize that during protein production and / or storage, the N-terminal glutamic acid (E) or glutamine (Q) may be cyclized to form a lactam (e.g., spontaneously or catalyzed by an enzyme present during production and / or storage). Therefore, in certain embodiments where the N-terminal residue of the amino acid sequence of the polypeptide is E or Q, the corresponding amino acid sequence in which E or Q is replaced by pyroglutamic acid is also contemplated herein.
[0279] The skilled artisan will also recognize that during protein production and / or storage, the C-terminal lysine (K) of a protein may be removed (e.g., spontaneously or catalyzed by enzymes present during production and / or storage). When using proteins comprising an Fc domain, such removal of K is typically found at the C-terminus. Therefore, in certain embodiments where the C-terminal residue of the amino acid sequence of a polypeptide (e.g., an Fc domain sequence) is K, the corresponding amino acid sequences where K is removed are also contemplated herein.
[0280] To obtain the highest yield of the multispecific binding protein, different ratios of the first, second, and third expression vectors can be explored to determine the optimal ratio for transfection into the host cell. After transfection, single clones can be isolated using methods known in the art, such as limiting dilution, ELISA, FACS, microscopy, or Clonepix, for cell bank production.
[0281] The clones can be cultured under conditions suitable for bioreactor scale-up and to maintain expression of the multispecific binding protein. The multispecific binding protein can be isolated and purified using methods known in the art including centrifugation, depth filtration, cell lysis, homogenization, freeze-thaw, affinity purification, gel filtration, ion exchange chromatography, hydrophobic interaction exchange chromatography, and mixed mode chromatography.
[0282] Pharmaceutical preparations
[0283] The present disclosure also provides pharmaceutical preparations containing a therapeutically effective amount of a multispecific binding protein disclosed herein (e.g., A49-F3'-TriNKET-trastuzumab). The pharmaceutical preparations contain one or more excipients and are maintained at a certain pH. As used herein, the term "excipient" means any non-therapeutic agent added to the formulation to provide a desired physical or chemical property, such as pH, osmotic pressure, viscosity, transparency, color, isotonicity, odor, sterility, stability, dissolution or release rate, adsorption or penetration.
[0284] Excipients and pH
[0285] The one or more excipients in the pharmaceutical formulation of the present invention include buffers. When used herein, the term "buffer" refers to one or more components that, when added to an aqueous solution, can protect the solution against changes in pH when an acid or base is added or after dilution with a solvent. In addition to phosphate buffers, glycinate, carbonate, citrate, histidine buffers, etc. can also be used, in which case sodium, potassium or ammonium ions can serve as counterions.
[0286] In certain embodiments, the buffer or buffer system comprises at least one buffer whose buffer range is completely or partially overlapped with the range of pH 5.5-7.4. In certain embodiments, the buffer has a pKa of about 6.0 ± 0.5. In certain embodiments, the buffer comprises a histidine buffer. In certain embodiments, the histidine is present in a concentration of 5 to 100mM, 10 to 100mM, 15 to 100mM, 20 to 100mM, 5 to 50mM, 10 to 50mM, 15 to 100mM, 20 to 100mM, 5 to 25mM, 10 to 25mM, 15 to 25mM, 20 to 25mM, 5 to 20mM, 10 to 20mM or 15 to 20mM. In certain embodiments, the histidine is present in a concentration of 5mM, 10mM, 15mM, 20mM, 25mM or 50mM. In certain embodiments, the histidine is present at a concentration of 20 mM.
[0287] The pharmaceutical preparation of the present invention can have a pH of 5.5 to 6.5. For example, in some embodiments, the pharmaceutical preparation has a pH of 5.5 to 6.5 (i.e. 6.0 ± 0.5), 5.6 to 6.4 (i.e. 6.0 ± 0.4), 5.7 to 6.3 (i.e. 6.0 ± 0.3), 5.8 to 6.2 (i.e. 6.0 ± 0.2), 5.9 to 6.1 (i.e. 6.0 ± 0.1) or 5.95 to 6.05 (i.e. 6.0 ± 0.05). In some embodiments, the pharmaceutical preparation has a pH of 5.5, 5.6, 5.7, 5.8, 5.9, 6.0, 6.1, 6.2, 6.3, 6.4 or 6.5. In some embodiments, the pharmaceutical preparation has a pH of 6.0. Under the scientific rounding rule, a pH greater than or equal to 5.95 and less than or equal to 6.05 is rounded to 6.0.
[0288] In certain embodiments, the buffer system of the pharmaceutical formulation comprises 10 to 25 mM histidine at a pH of 6.0 ± 0.2. In certain embodiments, the buffer system of the pharmaceutical formulation comprises 20 mM histidine at a pH of 6.0 ± 0.2. In certain embodiments, the buffer system of the pharmaceutical formulation comprises 10 to 25 mM histidine at a pH of 6.0 ± 0.05. In certain embodiments, the buffer system of the pharmaceutical formulation comprises 20 mM histidine at a pH of 6.0 ± 0.05.
[0289] The one or more excipients in the pharmaceutical preparation of the present invention also include sugar or sugar alcohol.Sugar and sugar alcohol can be used as heat stabilizers in pharmaceutical preparations.In certain embodiments, the pharmaceutical preparation comprises sugar, such as monosaccharide (glucose, xylose or erythritol), disaccharide (such as sucrose, trehalose, maltose or galactose) or oligosaccharide (such as stachyose).In a specific embodiment, the pharmaceutical preparation comprises sucrose.In certain embodiments, the pharmaceutical composition comprises sugar alcohol, such as sugar alcohol (such as mannitol, sorbitol or xylitol) derived from monosaccharide, sugar alcohol (such as lactitol or maltitol) derived from disaccharide or sugar alcohol derived from oligosaccharide.In a specific embodiment, the pharmaceutical preparation comprises sorbitol.
[0290] In some embodiments, the sugar or sugar alcohol included in the preparation can be changed with the specific circumstances and intended purpose of using the preparation. In some embodiments, the pharmaceutical preparation includes 50 to 300mM, 50 to 250mM, 100 to 300mM, 100 to 250mM, 150 to 300mM, 150 to 250mM, 200 to 300mM, 200 to 250mM or 250 to 300mM sugar or sugar alcohol. In some embodiments, the pharmaceutical preparation includes 50mM, 75mM, 100mM, 125mM, 150mM, 200mM, 250mM or 300mM sugar or sugar alcohol. In a specific embodiment, the pharmaceutical preparation includes 250mM sugar or sugar alcohol (such as sucrose or sorbitol).
[0291] The one or more excipients in the pharmaceutical formulation disclosed herein also include surfactants. When used in this article, the term "surfactant" refers to a surface-active molecule containing both a hydrophobic portion (e.g., an alkyl chain) and a hydrophilic portion (e.g., a carboxyl group and a carboxylate group). Surfactants can be used in pharmaceutical formulations to reduce the aggregation of therapeutic proteins. Suitable surfactants for use in the pharmaceutical formulations are generally nonionic surfactants, such as, but not limited to, polysorbates (e.g., polysorbate 20 or 80); poloxamers (e.g., poloxamer 188); sorbitan esters and derivatives; triaton; sodium lauryl sulfate; sodium octyl glucoside; lauryl-, myristyl-, linoleyl-, or stearyl-sulfobetaine; lauryl-, myristyl-, linoleyl-, or stearyl-sarcosine; linoleyl-, myristyl-, or cetyl-betaine; lauroyl-, cocamidopropyl-, linoleamidopropyl-, myristamidopropyl-, palmitamidopropyl-, or isostearamidopropyl-betaine (e.g., lauroyl); myristamidopropyl-, palmitamidopropyl-, or isostearamidopropyl-dimethylamine; sodium methyl cocoyl or disodium methyl oleyl taurate; and MONAQUAT TMSeries (Mona Industries, Inc., Paterson, NJ), polyethylene glycol, polypropylene glycol and copolymers of ethylene glycol and propylene glycol (e.g., Pluronics, PF68, etc.). In certain embodiments, the surfactant is a sorbitan ester. In certain embodiments, the surfactant is polysorbate 80.
[0292] The amount of the nonionic surfactant included in the pharmaceutical preparation of the present invention can change with the specific properties required for the preparation and the specific circumstances and purposes for which the preparation is intended. In certain embodiments, the pharmaceutical preparation comprises 0.005% to 0.5%, 0.005% to 0.2%, 0.005% to 0.1%, 0.005% to 0.05%, 0.005% to 0.02%, 0.005% to 0.01%, 0.01% to 0.5%, 0.01% to 0.2%, 0.01% to 0.1%, 0.01% to 0.05% or 0.01% to 0.02% of the nonionic surfactant (e.g., polysorbate 80). In certain embodiments, the pharmaceutical formulation comprises 0.005%, 0.01%, 0.02%, 0.03%, 0.04%, 0.05%, 0.06%, 0.07%, 0.08%, 0.09%, 0.1%, 0.15%, 0.2%, 0.25%, 0.3%, 0.35%, 0.4%, 0.45% or 0.5% of the non-ionic surfactant (e.g., polysorbate 80).
[0293] In certain embodiments, the pharmaceutical preparation is isotonic. An "isotonic" preparation is a preparation having substantially the same osmotic pressure as human blood. Isotonic preparations typically have an osmotic pressure of about 250 to 350 mOsmol / kgH2O. Isotonicity can be measured using a vapor pressure or frozen type osmometer. In certain embodiments, the osmotic pressure of the pharmaceutical preparation is 250 to 350 mOsmol / kgH2O. In certain embodiments, the osmotic pressure of the pharmaceutical preparation is 300 to 350 mOsmol / kgH2O.
[0294] The pharmaceutical preparation may include materials such as sugar, sugar alcohol and NaCl to obtain the desired osmotic pressure. In some embodiments, the concentration of NaCl in the pharmaceutical preparation, if present, is equal to or lower than 10mM, 9mM, 8mM, 7mM, 6mM, 5mM, 4mM, 3mM, 2mM, 1mM, 0.5mM, 0.1mM, 50μM, 10μM, 5μM or 1μM. In some embodiments, the concentration of NaCl in the pharmaceutical preparation is lower than the detection limit. In some embodiments, NaCl salt is not added when preparing the pharmaceutical preparation.
[0295] Pharmaceutical preparations of the present invention may also include one or more other substances, such as bulking agents or preservatives. "Bulking agents" are compounds that add mass to the lyophilized mixture and contribute to the physical structure of the lyophilized cake (e.g., facilitate the production of substantially uniform lyophilized cakes that maintain an open-cell structure). Illustrative bulking agents include mannitol, glycine, polyethylene glycol, and sorbitol. Lyophilized preparations of the present invention may contain such bulking agents. Preservatives may reduce the effects of bacteria and may, for example, promote the production of multipurpose (multiple dose) preparations.
[0296] Exemplary Formulations
[0297] In certain embodiments, a pharmaceutical formulation of the invention comprises a multispecific binding protein, histidine, a sugar or sugar alcohol (eg, sucrose or sorbitol), and a polysorbate (eg, polysorbate 80) and has a pH of 5.5 to 6.5.
[0298] In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 10 to 25 mM histidine, 200 to 300 mM sugar or sugar alcohol (e.g., sucrose or sorbitol), and 0.005% to 0.05% polysorbate (e.g., polysorbate 80), at a pH of 5.5 to 6.5. In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 20 mM histidine, 250 mM sugar or sugar alcohol (e.g., sucrose or sorbitol), and 0.01% polysorbate (e.g., polysorbate 80), at a pH of 5.5 to 6.5. In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 20 mM histidine, 250 mM sugar or sugar alcohol (e.g., sucrose or sorbitol) and 0.01% polysorbate (e.g., polysorbate 80), and the pH is 5.8 to 6.2. In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 20 mM histidine, 250 mM sugar or sugar alcohol (e.g., sucrose or sorbitol) and 0.01% polysorbate (e.g., polysorbate 80), and the pH is 5.95 to 6.05.
[0299] In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 10 to 25 mM histidine, 200 to 300 mM sucrose, and 0.005% to 0.05% polysorbate 80, and the pH is 5.5 to 6.5. In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 20 mM histidine, 250 mM sucrose, and 0.01% polysorbate 80, and the pH is 5.5 to 6.5. In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 20 mM histidine, 250 mM sucrose, and 0.01% polysorbate 80, and the pH is 5.8 to 6.2. In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 20 mM histidine, 250 mM sucrose, and 0.01% polysorbate 80, and has a pH of 5.95 to 6.05.
[0300] In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 10 to 25 mM histidine, 200 to 300 mM sorbitol, and 0.005% to 0.05% polysorbate 80, and the pH is 5.5 to 6.5. In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 20 mM histidine, 250 mM sorbitol, and 0.01% polysorbate 80, and the pH is 5.5 to 6.5. In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 20 mM histidine, 250 mM sorbitol, and 0.01% polysorbate 80, and the pH is 5.8 to 6.2. In certain embodiments, the pharmaceutical formulation comprises 10 to 50 mg / mL of the multispecific binding protein, 20 mM histidine, 250 mM sorbitol, and 0.01% polysorbate 80, and has a pH of 5.95 to 6.05.
[0301] Stability of multispecific binding proteins
[0302] The pharmaceutical formulations of the invention exhibit a high level of stability. A pharmaceutical formulation is stable when the multispecific binding protein in the formulation retains an acceptable degree of physical properties, chemical structure, and / or biological function after storage under defined conditions.
[0303] Stability can be measured by determining the percentage of multispecific binding proteins in the formulation that retain a native conformation after storage for a defined amount of time at a defined temperature. The percentage of proteins in a native conformation can be determined, for example, by size exclusion chromatography (e.g., size exclusion high performance liquid chromatography), wherein proteins in a native conformation do not aggregate (elute in a high molecular weight fraction) or degrade (elute in a low molecular weight fraction). In certain embodiments, after incubation at 4°C for 3 weeks, more than 95%, 96%, 97%, 98%, or 99% of the multispecific binding protein has a native conformation when measured by size exclusion chromatography. In certain embodiments, after incubation at 50°C for 3 weeks, more than 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% of the multispecific binding protein has a native conformation when measured by size exclusion chromatography. In certain embodiments, after incubation at 4°C for 3 weeks, less than 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1% of the multispecific binding protein forms high molecular weight complexes (i.e., has a higher molecular weight than the native protein) when measured by size exclusion chromatography. In certain embodiments, after incubation at 50°C for 3 weeks, less than 1%, 2%, 3%, 4%, or 5% of the multispecific binding protein forms high molecular weight complexes (i.e., has a higher molecular weight than the native protein) when measured by size exclusion chromatography. In certain embodiments, after incubation at 4°C for 3 weeks, less than 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, or 1% of the multispecific binding protein is degraded (i.e., has a lower molecular weight than the native protein) when measured by size exclusion chromatography. In certain embodiments, after incubation at 50°C for 3 weeks, less than 1%, 1.5%, 2%, 2.5% or 3% of the multispecific binding protein is degraded (ie, has a lower molecular weight than the native protein) as determined by size exclusion chromatography.
[0304] Stability can also be measured by determining the percentage of the multispecific binding protein present in the more acidic fraction ("acidic form") relative to the major fraction of the protein ("major charged form"). Without wishing to be limited by theory, deamidation of a protein may cause it to become more negatively charged and therefore more acidic relative to the non-deamidated protein (see, e.g., Robinson, Protein Deamidation (2002) PNAS 99(8):5283-88). The percentage of the acidic form of the protein can be determined by ion exchange chromatography (e.g., cation exchange high performance liquid chromatography) or imaged capillary isoelectric focusing (icIEF). In certain embodiments, after incubation at 4°C for 3 weeks, at least 50%, 60%, 70%, 80%, or 90% of the multispecific binding protein in the pharmaceutical formulation is in the major charged form. In certain embodiments, at least 15%, 20%, 25%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the multispecific binding protein in the pharmaceutical formulation is in the predominantly charged form after incubation at 50° C. for 3 weeks. In certain embodiments, no more than 10%, 20%, 30%, 40%, or 50% of the multispecific binding protein in the pharmaceutical formulation is in the acidic form after incubation at 4° C. for 3 weeks. In certain embodiments, no more than 10%, 20%, 30%, 40%, 50%, 60%, 70%, 75%, 80%, or 85% of the multispecific binding protein in the pharmaceutical formulation is in the acidic form after incubation at 50° C. for 3 weeks.
[0305] Stability can also be measured by determining the purity of the multispecific binding protein by electrophoresis after denaturing the protein with sodium dodecyl sulfate (SDS). The protein sample can be denatured in the presence or absence of an agent that reduces disulfide bonds of the protein (e.g., β-mercaptoethanol). In certain embodiments, the purity of the multispecific binding protein in the pharmaceutical formulation measured by capillary electrophoresis after denaturing the protein sample under reducing conditions (e.g., in the presence of β-mercaptoethanol) after incubation at 4°C for 3 weeks is at least 95%, 96%, 97%, 98%, or 99%. In certain embodiments, the purity of the multispecific binding protein in the pharmaceutical formulation measured by capillary electrophoresis after denaturing the protein sample under reducing conditions (e.g., in the presence of β-mercaptoethanol) after incubation at 50°C for 3 weeks is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%. In certain embodiments, the purity of the multispecific binding protein in the pharmaceutical formulation as measured by capillary electrophoresis after denaturing the protein sample under non-reducing conditions after incubation at 4° C. for 3 weeks is at least 95%, 96%, 97%, 98%, or 99%. In certain embodiments, the purity of the multispecific binding protein in the pharmaceutical formulation as measured by capillary electrophoresis after denaturing the protein sample under non-reducing conditions after incubation at 50° C. for 3 weeks is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99%.
[0306] Stability can also be measured by determining the parameters of the protein solution through dynamic light scattering. Z-mean and polydispersity index (PDI) values indicate the average diameter of particles in solution, and these measurements increase when aggregates are present in solution. The monomer % Pd value indicates the distribution of different monomers detected, where a lower value indicates a monodisperse solution, which is preferred. The monomer size detected by DLS can be used to confirm that the main population is a monomer and to characterize any higher order aggregates that may be present. In certain embodiments, after incubation at 4°C for 3 weeks, the increase in the Z-mean of the pharmaceutical preparation does not exceed 5%, 10%, or 15%. In certain embodiments, after incubation at 50°C for 3 weeks, the increase in the Z-mean of the pharmaceutical preparation does not exceed 5%, 10%, 15%, 20%, or 25%. In certain embodiments, after incubation at 4°C for 3 weeks, the increase in the PDI value of the pharmaceutical preparation does not exceed 10%, 20%, 30%, 40%, or 50%. In certain embodiments, after incubation at 50° C. for 3 weeks, the PDI value of the pharmaceutical formulation does not increase by more than 2-fold, 3-fold, 4-fold, or 5-fold.
[0307] Exemplary methods for determining the stability of the multispecific binding protein in the pharmaceutical formulation are described in Example 1 of the present disclosure. In addition, the stability of the protein can be assessed by measuring the binding affinity of the multispecific binding protein to its target or the biological activity of the multispecific binding protein in certain in vitro assays such as the NK cell activation assay and cytotoxicity assay described in WO 2018 / 152518.
[0308] Dosage form
[0309] The pharmaceutical preparation can be prepared and stored as a liquid preparation or a lyophilized form. In certain embodiments, the pharmaceutical preparation is a liquid preparation for storage at 2-8°C (e.g., 4°C) or a frozen preparation for storage at -20°C or lower. The sugar or sugar alcohol in the preparation is used as a lyoprotectant.
[0310] Before the drug is used, the pharmaceutical preparation can be diluted or reconstituted in an aqueous carrier suitable for the route of administration. Other exemplary carriers include sterile water for injection (SWFI), bacteriostatic water for injection (BWFI), pH buffer solution (e.g., phosphate buffered saline), sterile saline solution, Ringer's solution, or dextrose solution. For example, when the pharmaceutical preparation is prepared for intravenous administration, the pharmaceutical preparation can be diluted in 0.9% sodium chloride (NaCl) solution. In some embodiments, the diluted pharmaceutical preparation is isotonic and is suitable for administration by intravenous infusion.
[0311] The pharmaceutical formulation comprises the multispecific binding protein at a concentration suitable for storage. In certain embodiments, the pharmaceutical formulation comprises the multispecific binding protein at a concentration of 10-50 mg / mL, 10-40 mg / mL, 10-30 mg / mL, 10-25 mg / mL, 10-20 mg / mL, 10-15 mg / mL, 15-50 mg / mL, 15-40 mg / mL, 15-30 mg / mL, 15-25 mg / mL, 15-20 mg / mL, 20-50 mg / mL, 20-40 mg / mL, 20-30 mg / mL, 20-25 mg / mL, 30-50 mg / mL, 30-40 mg / mL, or 40-50 mg / mL. In certain embodiments, the pharmaceutical formulation comprises the multispecific binding protein at a concentration of 10 mg / mL, 11 mg / mL, 12 mg / mL, 13 mg / mL, 14 mg / mL, 15 mg / mL, 16 mg / mL, 17 mg / mL, 18 mg / mL, 19 mg / mL, 20 mg / mL, 25 mg / mL, 30 mg / mL, 35 mg / mL, 40 mg / mL, 45 mg / mL, or 50 mg / mL.
[0312] In certain embodiments, the pharmaceutical preparation is packaged in a container (e.g., a vial, a bag, a pen, or a syringe). In certain embodiments, the preparation can be a lyophilized preparation or a liquid preparation. In certain embodiments, the amount of the multispecific binding protein in the container is suitable for administration as a single dose. In certain embodiments, the amount of the multispecific binding protein in the container is suitable for multiple doses. In certain embodiments, the pharmaceutical preparation comprises the multispecific binding protein in an amount of 0.1 to 2000 mg. In certain embodiments, the pharmaceutical preparation is 1 to 2000 mg, 10 to 2000 mg, 20 to 2000 mg, 50 to 2000 mg, 100 to 2000 mg, 200 to 2000 mg, 500 to 2000 mg, 1000 to 2000 mg, 0.1 to 1000 mg, 1 to 1000 mg, 10 to 1000 mg, 20 to 1000 mg, 50 to 1000 mg, 100 to 1000 mg, 200 to 1000 mg, 500 to 1000 mg, 0.1 to 500 mg, 1 to 500 mg, 10 to 500 mg, 20 to 500 mg, 50 The multispecific binding protein may be present in an amount of 0.1 to 500 mg, 100 to 500 mg, 200 to 500 mg, 0.1 to 200 mg, 1 to 200 mg, 10 to 200 mg, 20 to 200 mg, 50 to 200 mg, 100 to 200 mg, 0.1 to 100 mg, 1 to 100 mg, 10 to 100 mg, 20 to 100 mg, 50 to 100 mg, 0.1 to 50 mg, 1 to 50 mg, 10 to 50 mg, 20 to 50 mg, 0.1 to 20 mg, 1 to 20 mg, 10 to 20 mg, 0.1 to 10 mg, 1 to 10 mg or 0.1 to 1 mg. In certain embodiments, the pharmaceutical formulation comprises the multispecific binding protein in an amount of 0.1 mg, 1 mg, 2 mg, 5 mg, 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg, 80 mg, 90 mg, 100 mg, 150 mg, 200 mg, 250 mg, 300 mg, 400 mg, 500 mg, 600 mg, 700 mg, 800 mg, 900 mg, 1000 mg, 1500 mg or 2000 mg.
[0313] Dosage regimen and therapeutic use
[0314] In another aspect, the present disclosure provides a method of treating cancer, comprising administering a multispecific binding protein disclosed herein (e.g., A49-F3'-TriNKET-trastuzumab) to a subject in need thereof on day 1, day 8, and day 15 of an initial 4-week treatment cycle. In certain embodiments, the multispecific binding protein is administered to the subject only on these three days of the initial 4-week treatment cycle. In a specific embodiment, the multispecific binding protein is not administered to the subject on day 22. This regimen is a dose intensification plan designed to achieve maximum saturation of the target as early as possible during treatment while minimizing the infusion burden on the patient.
[0315] In certain embodiments, the method further comprises administering the multispecific binding protein to the subject in one or more subsequent 4-week treatment cycles after the initial treatment cycle, wherein the multispecific binding protein is administered on day 1 and day 15 in each subsequent treatment cycle. In certain embodiments, the multispecific binding protein is administered to the subject only on these two days in each subsequent 4-week treatment cycle. In a specific embodiment, the multispecific binding protein is not administered to the subject on day 8 or day 22. The subsequent treatment cycles in which the subject receives administration of the multispecific binding protein once every two weeks are designed to maintain the multispecific binding protein in the subject at a certain level. In certain embodiments, the subject receives at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 subsequent treatment cycles. In certain embodiments, the subject receives subsequent treatment cycles until the cancer regresses.
[0316] In certain embodiments, one or more doses in the initial and subsequent treatment cycles comprise the multispecific binding protein in an amount of 0.1-20 mg / kg, 0.1-10 mg / kg, 0.1-5 mg / kg, 0.1-2 mg / kg, 0.1-1 mg / kg, 0.1-0.5 mg / kg, 0.1-0.2 mg / kg, 0.2-20 mg / kg, 0.2-10 mg / kg, 0.2-5 mg / kg, 0.2-2 mg / kg, 0.2-1 mg / kg, 0.2-0.5 mg / kg, 0.5-20 mg / kg, 0.5-10 mg / kg, 0.5-5 mg / kg, 0.5-2 mg / kg, 0.5-1 mg / kg, 1-20 mg / kg, 1-10 mg / kg, 1-5 mg / kg, or 1-2 mg / kg. In certain embodiments, one or more doses in the initial and subsequent treatment cycles comprise the multispecific binding protein in an amount selected from 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, and 20 mg / kg.
[0317] In certain embodiments, each dose in the initial and subsequent treatment cycles comprises the multispecific binding protein in an amount selected from the group consisting of 0.1-20 mg / kg, 0.1-10 mg / kg, 0.1-5 mg / kg, 0.1-2 mg / kg, 0.1-1 mg / kg, 0.1-0.5 mg / kg, 0.1-0.2 mg / kg, 0.2-20 mg / kg, 0.2-10 mg / kg, 0.2-5 mg / kg, 0.2-2 mg / kg, 0.2-1 mg / kg, 0.2-0.5 mg / kg, 0.5-20 mg / kg, 0.5-10 mg / kg, 0.5-5 mg / kg, 0.5-2 mg / kg, 0.5-1 mg / kg, 1-20 mg / kg, 1-10 mg / kg, 1-5 mg / kg, and 1-2 mg / kg. In certain embodiments, each dose in the initial and subsequent treatment cycles comprises the multispecific binding protein in the same amount selected from 0.1-20 mg / kg, 0.1-10 mg / kg, 0.1-5 mg / kg, 0.1-2 mg / kg, 0.1-1 mg / kg, 0.1-0.5 mg / kg, 0.1-0.2 mg / kg, 0.2-20 mg / kg, 0.2-10 mg / kg, 0.2-5 mg / kg, 0.2-2 mg / kg, 0.2-1 mg / kg, 0.2-0.5 mg / kg, 0.5-20 mg / kg, 0.5-10 mg / kg, 0.5-5 mg / kg, 0.5-2 mg / kg, 0.5-1 mg / kg, 1-20 mg / kg, 1-10 mg / kg, 1-5 mg / kg, and 1-2 mg / kg.
[0318] In certain embodiments, each dose in the initial and subsequent treatment cycles comprises the multispecific binding protein in an amount selected from 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, and 20 mg / kg. In certain embodiments, each dose in the initial and subsequent treatment cycles comprises the multispecific binding protein in the same amount selected from 0.1 mg / kg, 0.2 mg / kg, 0.3 mg / kg, 0.4 mg / kg, 0.5 mg / kg, 0.6 mg / kg, 0.7 mg / kg, 0.8 mg / kg, 0.9 mg / kg, 1 mg / kg, 1.5 mg / kg, 2 mg / kg, 2.5 mg / kg, 3 mg / kg, 4 mg / kg, 5 mg / kg, 6 mg / kg, 7 mg / kg, 8 mg / kg, 9 mg / kg, 10 mg / kg, 11 mg / kg, 12 mg / kg, 13 mg / kg, 14 mg / kg, 15 mg / kg, 16 mg / kg, 17 mg / kg, 18 mg / kg, 19 mg / kg, and 20 mg / kg.
[0319] In certain embodiments, each of the agents in the initial and subsequent treatment cycles is selected from 5.2×10 -5 mg / kg, 1.6×10 -4 mg / kg, 5.2×10 -4 mg / kg, 1.6×10 -3 mg / kg, 5.2×10 -3 mg / kg, 1.6×10 -2 mg / kg, 5.2×10 -2 mg / kg, 1.6×10 -1 The multispecific binding protein is included in an amount selected from 5.2×10 -5 mg / kg, 1.6×10 -4 mg / kg, 5.2×10 -4mg / kg, 1.6×10 -3 mg / kg, 5.2×10 -3 mg / kg, 1.6×10 -2 mg / kg, 5.2×10 -2 mg / kg, 1.6×10 -1 The same amounts of 1 mg / kg, 0.52 mg / kg, 1 mg / kg, 1.6 mg / kg, 5.2 mg / kg, 10 mg / kg, 20 mg / kg and 50 mg / kg comprise the multispecific binding protein.
[0320] In certain embodiments, the multispecific binding protein is administered intravenously. For example, in certain embodiments, the multispecific binding protein is administered by intravenous infusion, for example using a prefilled bag, a prefilled pen, or a prefilled syringe. In certain embodiments, the multispecific binding protein in the pharmaceutical preparation disclosed herein is diluted prior to administration. For example, in certain embodiments, the pharmaceutical preparation is diluted with sodium chloride and administered intravenously from a 250 ml saline bag. The intravenous infusion can be performed for about 1 hour (e.g., 50 to 80 minutes). In certain embodiments, the bag is connected to a channel comprising a tube and / or a needle.
[0321] Cancer types that can be treated with the multispecific binding proteins or pharmaceutical formulations disclosed herein include, but are not limited to, breast cancer, thyroid cancer, gastric cancer, renal cell carcinoma, lung adenocarcinoma, prostate cancer, bile duct cancer, uterine cancer, pancreatic cancer, colorectal cancer, ovarian cancer, cervical cancer, head and neck cancer, NSCLC, glioblastoma, esophageal cancer, skin squamous cell carcinoma, salivary gland cancer, biliary tract cancer, lung squamous cell carcinoma, mesothelioma, liver cancer, sarcoma, bladder cancer, and gallbladder cancer. In certain embodiments, the cancer is a solid tumor. In certain embodiments, the cancer is a locally advanced or metastatic solid tumor. In certain embodiments, the cancer is urothelial bladder cancer or metastatic breast cancer.
[0322] In certain embodiments, the subject treated by the methods disclosed herein suffers from a HER2-positive cancer. Methods for determining the expression of HER2 in cancer include, but are not limited to, immunohistochemistry. Anti-HER2 antibodies (e.g., Ventana 4B5 antibody and Bond Oracle CB11 antibody) have been approved by the FDA for detection of HER2, and immunohistochemistry kits (e.g., HercepTest TM) is commercially available. When detected by immunohistochemistry, the HER2 expression level in the tumor sample can be quantified and scored as 1+, 2+ or 3+ according to the ASCO / CAP guidelines (Wolff et al., (2007) J.Clin.Oncol.25(1):118-45). In certain embodiments, the subject treated by the methods disclosed herein has a tumor whose HER2 level is scored as 1+, 2+ or 3+. In certain embodiments, the subject treated by the methods disclosed herein has a tumor whose HER2 level is scored as 2+ or 3+. In certain embodiments, the subject treated by the methods disclosed herein has a tumor whose HER2 level is scored as 3+. In certain embodiments, the HER2 level is measured by immunohistochemistry (e.g., HercepTest TM ). In certain embodiments, the tumors of subjects treated by the methods disclosed herein show HER2 expression with at least weak / barely detectable membrane staining detected in at least or more than 10% of tumor cells. In certain embodiments, the tumors of subjects treated by the methods disclosed herein show HER2 expression with at least weak to moderate complete membrane staining detected in at least or more than 10% of tumor cells. In certain embodiments, the tumors of subjects treated by the methods disclosed herein show HER2 expression with at least strong complete membrane staining detected in at least or more than 10% of tumor cells.
[0323] In certain embodiments, the subject treated by the methods disclosed herein suffers from cancer with ERBB2 gene amplification. ERBB2 gene amplification is associated with HER2 overexpression, and determining whether the ERBB2 gene is amplified in a cancer tissue sample can help reduce false positive results from immunohistochemistry of the same sample (see, e.g., Sarode et al., (2015) Arch. Pathol. Lab. Med. 139: 922–28). Methods for detecting gene amplification include, but are not limited to, fluorescent in situ hybridization (FISH), chromogenic in situ hybridization (CISH), quantitative PCR, and DNA sequencing. In certain embodiments, ERBB2 gene amplification is determined by FISH. In certain embodiments, ERBB2 gene amplification is determined by DNA sequencing (e.g., deep sequencing).
[0324] In certain embodiments, the subject treated according to the methods disclosed herein has not received a previous therapy for treating the cancer. In certain embodiments, the subject treated according to the methods disclosed herein has not received a previous chemotherapy or immunotherapy for treating the cancer. In certain embodiments, the subject treated according to the methods disclosed herein has received a previous treatment (e.g., chemotherapy or immunotherapy), but continues to experience cancer progression despite receiving the previous treatment. In certain embodiments, the subject treated according to the methods disclosed herein has experienced cancer regression after receiving a previous treatment (e.g., chemotherapy or immunotherapy), but experiences cancer recurrence at a later time. In certain embodiments, the subject treated according to the methods disclosed herein is intolerant to a previous treatment (e.g., chemotherapy or immunotherapy).
[0325] In certain embodiments, the subject treated according to the methods disclosed herein meets all the inclusion criteria of the clinical trial cohorts described in Example 3 (e.g., accelerated titration cohort, "3+3" dose escalation cohort, safety / PK / PD expansion cohort, urothelial bladder cancer (UBC) cohort, metastatic breast cancer (MBC) cohort, basket solid tumor cohort with high HER2 expression (HER2 3+), or combination treatment cohort with pembrolizumab). In certain embodiments, the subject treated according to the methods disclosed herein does not meet any of the exclusion criteria described in Example 3.
[0326] The multispecific binding proteins disclosed herein can be used as a monotherapy or in combination with one or more therapies. In certain embodiments, the multispecific binding proteins are used as a monotherapy according to the dosage regimen disclosed herein. In other embodiments, the multispecific binding proteins are used in combination with one or more therapies, wherein the multispecific binding proteins are administered according to the dosage regimen disclosed herein, and the one or more therapies are administered according to a dosage regimen known to be suitable for treating a specific subject with a specific cancer. In certain embodiments, the treatment methods disclosed herein are used as an adjunct to surgical removal of the primary lesion.
[0327] Exemplary therapeutic agents that can be used in combination with the multispecific binding proteins include, for example, radiation, mitomycin, retinoic acid, nivolumab, gemcitabine, vincristine, etoposide, cladribine, dibromomannitol, methotrexate, doxorubicin, carboquinone, pentostatin, nitracrine, nivolumab, cetrorelix, letrozole, raltitrexed, daunorubicin, fadrozole, fotemustine, thymalfasin, sobuzosane, nedaplatin, cytarabine, bicalutamide, vinorelbine, vesanaline, aminoglutethimide, amsacrine, proglumide, elixirsium acetate, ketanserin, doxifluridine, etretinate, isotretinoin, streptozotocin, nimustine, vindesine, flutamide, dro genil, butocin, carmofur, razoxane, sizofilan, carboplatin, dibromodulin, tegafur, ifosfamide, prednimustine, sapellose, levamisole, teniposide, improsulfan, enocitabine, lisuride, oxymetholone, tamoxifen, progesterone, melastane, cyclothiodine, formestran, interferon-α, interferon-2α, interferon-β, interferon-γ (IFN-γ), colony stimulating factor-1, colony stimulating factor-2, denileukin, interleukin-2, luteinizing hormone releasing factor, and any variations of the foregoing agents that may exhibit differential binding to their cognate receptors or increased or decreased serum half-life.
[0328] Another class of agents that can be used as part of a combination therapy in the treatment of cancer is an immune checkpoint inhibitor. Exemplary immune checkpoint inhibitors include inhibitors that inhibit one or more of the following: (i) cytotoxic T lymphocyte-associated antigen 4 (CTLA4), (ii) programmed cell death protein 1 (PD1), (iii) PDL1, (iv) LAG3, (v) B7-H3, (vi) B7-H4, and (vii) TIM3. The CTLA4 inhibitor Ipilimumab has been approved by the United States Food and Drug Administration for the treatment of melanoma.
[0329] Other agents that may be used as part of a combination therapy in treating cancer are monoclonal antibody agents directed against non-checkpoint targets (eg, Herceptin) and non-cytotoxic agents (eg, tyrosine kinase inhibitors).
[0330] Another class of anticancer agents includes, for example: (i) an ALK inhibitor, an ATR inhibitor, an A2A antagonist, a base excision repair inhibitor, a Bcr-Abl tyrosine kinase inhibitor, a Bruton's tyrosine kinase inhibitor, a CDC7 inhibitor, a CHK1 inhibitor, a cyclin-dependent kinase inhibitor, a DNA-PK inhibitor, an inhibitor of both DNA-PK and mTOR, a DNMT1 inhibitor, a DNMT1 inhibitor plus 2-chloro-deoxyadenosine, an HDAC inhibitor, an inhibitor of the hedgehog signaling pathway, an IDO inhibitor, a JAK inhibitor, an mTOR inhibitor, preparation, a MEK inhibitor, a MELK inhibitor, an MTH1 inhibitor, a PARP inhibitor, an inhibitor of phosphoinositide 3-kinase, an inhibitor of both PARP1 and DHODH, a proteasome inhibitor, a topoisomerase-II inhibitor, a tyrosine kinase inhibitor, a VEGFR inhibitor, and a WEE1 inhibitor; (ii) an agonist of OX40, CD137, CD40, GITR, CD27, HVEM, TNFRSF25, or ICOS; and (iii) a cytokine selected from IL-12, IL-15, GM-CSF, and G-CSF.
[0331] In certain embodiments, the methods of the present invention further comprise administering an anti-PD-1 antibody to the subject. Many anti-PD-1 antibodies have been developed for therapeutic purposes, which are described, for example, in Gong et al., (2018) J. ImmunoTher Cancer (2018) 6:8. In certain embodiments, the anti-PD-1 antibody is pembrolizumab. In certain embodiments, 200 mg of pembrolizumab is administered on day 1 of the initial treatment cycle. In certain embodiments, if the subject receives one or more subsequent treatment cycles, 200 mg of pembrolizumab is administered once every three weeks in the subsequent treatment cycles starting from day 1 of the first subsequent treatment cycle.
[0332] In certain embodiments, the methods disclosed herein cause the subject or patient's disease response or improve their survival. For example, in certain embodiments, the disease response is a complete response, a partial response or a stable disease. In certain embodiments, the improved survival is an improved progression-free survival (PFS) or overall survival. Improvement (for example, in terms of PFS) can be determined relative to the time period before the treatment of the present disclosure begins. For BTC (for example, advanced BTC, metastatic BTC) or biliary tumor therapy, the method for determining disease response (for example, complete response, partial response or stable disease) and patient survival (for example, PFS, overall survival) is conventional in the art and considered herein. In certain embodiments, the disease response is evaluated according to RECIST 1.1 after contrast-enhanced computed tomography (CT) is performed on the treated patient or magnetic resonance imaging (MRI) is performed on the affected area (for example, the chest / abdomen and pelvis covering the area from above the thoracic inlet to the pubic symphysis). Example
[0333] The present disclosure, now being generally described, will be more readily understood by reference to the following examples, which are included merely for the purpose of illustrating certain aspects and embodiments of the disclosure and are not intended to limit the scope of the disclosure in any way.
[0334] Example 1: Formulation, packaging and storage of A49-F3'-TriNKET-trastuzumab
[0335] The formulations listed in Table 12 were evaluated in duplicate and randomized to evaluate the effects of pH and excipients on the stability of A49-F3'-TriNKET-trastuzumab (Kermit BDS batch number 7443-C3, 11.9 mg / mL). A49-F3'-TriNKET-trastuzumab was buffer exchanged in the corresponding buffer and excipient combination by centrifugal ultrafiltration (Amicon Ultra-4 30k device MWCO) to a target concentration of 30 mg / mL. After the final buffer exchange and confirmation of the target concentration, each formulated sample was sterilized by filtration using a 0.22 μm EMDMillipore Ultrafree–CL centrifugal filter device with a Durapore membrane (Fisher Scientific catalog number UFC40GVOS). After sterile filtration, each formulation was aseptically manipulated in a laminar flow hood. Polysorbate 80 (PS80) was added to the formulated sample to a final concentration of 0.01%. An aliquot of each formulation was taken out for time zero testing, and the remaining material was divided into two equal parts, placed in 2mL x 13mm depyrogenated type 1 borosilicate glass vials (West Pharmaceuticals catalog number 68000377), plugged and sealed with 13mm Fluorotec stoppers (West Pharmaceuticals catalog number 19700302). The time zero aliquot was used for initial time point testing according to Table 13. One vial was stored at 2-8°C and the other vial was placed at 50°C for a 3-week accelerated stability study. After 3 weeks of incubation, the 2-8°C and 50°C samples were analyzed according to the test method indicated in Table 13.
[0336] Table 12. Formulations evaluated
[0337]
[0338] Table 13. Panel of assays used in formulation evaluation
[0339]
[0340] An accelerated stability study of A49-F3'-TriNKET-trastuzumab was performed in which A49-F3'-TriNKET-trastuzumab was prepared in 20 formulations as shown in Table 12. Samples were run in duplicate and incubated at 2-8°C and 50°C for 3 weeks. At time zero and at the end of the 3-week incubation, each formulated sample was tested using the assays outlined in Table 13. All formulations behaved similarly and within the expected range as assessed by appearance, concentration, pH, and osmolarity.
[0341] Appearance
[0342] Before the sample bottles were opened, the samples were observed against black and white backgrounds under laboratory ambient conditions. All samples showed no visible particulate matter at both time zero and three weeks.
[0343] UV concentration measurement
[0344] For each sample and condition, protein concentration was determined by ultraviolet (UV) absorption at optical density (OD) 280 nm. The protein concentrations at time zero, after 3 weeks of incubation at 2-8°C, and after 3 weeks of incubation at 50°C are summarized in Table 14.
[0345] pH determination
[0346] The pH was determined for each sample and condition. The pH values at time zero, after 3 weeks of incubation at 2-8°C, and after 3 weeks of incubation at 50°C are summarized in Table 15.
[0347] Dynamic Light Scattering
[0348] Dynamic light scattering (DLS) samples were collected after 300 seconds equilibration at 25°C. Five measurements were taken for each sample. The Z-mean values at time zero, after 3 weeks of incubation at 2-8°C, and after 3 weeks of incubation at 50°C are summarized in Table 16.
[0349] The mean polydispersity index (%PDI) was also reported. The %PDI values at time zero, after 3 weeks of incubation at 2-8°C and after 3 weeks of incubation at 50°C are summarized in Table 17.
[0350] Additional DLS analysis of A49-F3'-TriNKET-trastuzumab in the samples was also performed. The average monomer polydispersity percentage (% PD) at time zero, after 3 weeks of incubation at 2-8°C, and after 3 weeks of incubation at 50°C are summarized in Table 18. The average monomer size values at time zero, after 3 weeks of incubation at 2-8°C, and after 3 weeks of incubation at 50°C are summarized in Table 19.
[0351] Table 14. Protein concentration calculated from UV absorbance
[0352]
[0353] Table 15. pH values
[0354]
[0355]
[0356] Table 16. Z-means from DLS
[0357]
[0358] Table 17. PDI values from DLS
[0359]
[0360]
[0361] Table 18. Monomer % PD values
[0362]
[0363] Table 19. Monomer size values
[0364]
[0365]
[0366] As assessed by DLS, all A49-F3'-TriNKET-trastuzumab formulations exhibited conformational stability with average and monomer sizes ≤20 nm and polydispersity (PDI) ≤0.300. Of the excipient and pH combinations evaluated, formulations with only sorbitol and sucrose had lower average sizes relative to the combined formulations of NaCl with sorbitol and NaCl with sucrose after 3 weeks of incubation at 2-8°C and 50°C (comparative models are shown in Figure 2A and Figure 2B After 3 weeks of incubation at 2–8°C and 50°C, the average monomer size was also lower in the sorbitol and sucrose alone formulations compared to the combined formulations with NaCl ( Figure 3A and 3B ).
[0367] Size Exclusion Chromatography (SEC)
[0368] Size exclusion chromatography was performed according to the protocol method to determine the percentage of high molecular weight species (%HMW), the percentage of main species (%Main), and the percentage of low molecular weight species (%LMW). The samples were diluted to 2.0 mg / mL in mobile phase buffer (containing 100 mM phosphate, 150 mM sodium chloride, pH 7.3) and injected at 100 μg load. Separation was performed using a Tosoh G3000SWxl (7.8 x 300 mm, catalog number 08541) column with a detection wavelength of 280 nm and a bandwidth of 8 nm. Samples were analyzed in real time at time zero and after incubation at 2–8°C or 50°C for 3 weeks. The %HMW values are summarized in Table 20, the %main values are summarized in Table 21, and the %LMW values are summarized in Table 22.
[0369] Table 20. % HMW SEC
[0370]
[0371]
[0372] Table 21. % Main Peak SEC
[0373]
[0374] Table 22. %LMW SEC
[0375]
[0376]
[0377] After incubation at 50°C for 3 weeks, the formulated samples had a % Main Peak in the range of 91.3%-95.2%, with those formulations with only sorbitol and sucrose maintaining a larger % Main Peak and lower % HMW species (shown in Figure 4A and Figure 5A Importantly, the single excipients sucrose and sorbitol both maintained % of main peak material over the pH range of 5.5–6.5, and both exhibited only slightly increased % HMW material as pH increased from 5.5 to 6.5. For all excipients, % LMW material tended to be lower as pH increased from 5.5 to about 6.2 ( Fig. 6A ).
[0378] After 3 weeks of incubation at 2–8°C, all formulated samples maintained greater than 98% of the major peak. Figure 4B As shown in , the % main peak is larger at lower pH (5.5) than at higher pH (pH 6.5). The single excipients sorbitol and sucrose tend to have lower % HMW relative to the combined excipients of NaCl with sorbitol and NaCl with sucrose. For all excipients, increased pH tends to increase % HMW species ( Figure 4B ). The %LMW species tended to be lower for the combined excipients but was independent of pH ( Figure 6B ).
[0379] Osmotic pressure
[0380] The osmotic pressure (osmo) of all samples was measured by freezing point depression method. All samples maintained osmotic pressure under all conditions. The osmotic pressure data at time zero, after 3 weeks of incubation at 2-8°C and after 3 weeks of incubation at 50°C are summarized in Table 23.
[0381] Table 23. Osmotic pressure values
[0382]
[0383] Imaged capillary isoelectric focusing (icIEF)
[0384] In order to determine the charge variant analysis, imaging capillary isoelectric focusing (icIEF) was used. Charge heterogeneity was assessed using the simple protein-Maurice's draft method. Starting material and sample were diluted to 5 mg / mL in water, then merged with the master mixture, and 10 μL samples were added to 90 μL master mixtures. The master mixture was a combination of 1% methylcellulose, Pharmalyte 3-10, Pharmalyte 8-10.5, pI marker 5.12, pI marker 9.50 and DI water. Before running samples in a 96-well plate format, system suitability standards were prepared and run. The method parameters for Maurice are as follows: #1 focusing period = 1 min, 1500 V, #2 focusing period = 8 min, 3000 V, detection = 5 exposures, loading = 55 s, lower limit pI marker = 5.12, 300 pixels, upper limit pI marker = 9.50, 1800 pixels. Every 18 injections were run once for starting material to ensure consistent readings.
[0385] The "Main Peak" is identified as the main peak in the formulated sample at time zero. After incubation, the peak with the same elution time may decrease and no longer represent the peak with the largest area under the curve, but is still identified as the "Main Peak". The percentage values of protein present in the acidic fraction after 3 weeks of incubation at 2-8°C and after 3 weeks of incubation at 50°C (% Acidic) are summarized in Table 24. The percentage values of protein present in the main peak fraction (% Main Peak) are summarized in Table 25. The percentage values of protein present in the basic fraction (% Basic) are summarized in Table 26.
[0386] Table 24. % Acidic icIEF
[0387]
[0388] Table 25. % Main Peak icIEF
[0389]
[0390] Table 26. % Basic Peak icIEF
[0391]
[0392]
[0393] For the formulated samples, after 3 weeks of incubation at 2–8°C, the % Main Peak ranged from 58.3%–62.2%, the % Acidic values ranged from 34.3%–38.4%, and the % Basic values ranged from 3.3%–3.7%. No significant model fit the % Main Peak data, indicating that neither pH nor excipients had a significant effect on the icIEF values ( Figures 8B-8D Excipients were also not significant in modeling % acidic and % basic, and % acidic tended to increase with pH, while % basic decreased ( Figure 7B and 9B ). However, as can be observed by the narrow range of all values, the changes are marginal.
[0394] For the formulated samples, after 3 weeks of incubation at 50°C, the % Main Peak ranged from 14.9%–22.7%, the % Acidity values ranged from 70.6%–81.6%, and the % Basicity values ranged from 2.4%–8.8%. The data showed a shift from % Main Peak material to % Acidity material compared to the results of 3 weeks of incubation at 2–8°C, while % Basicity remained relatively consistent. Among the formulated samples evaluated at 50°C for 3 weeks, the sample with sucrose as the sole excipient had the highest % Acidity material ( Fig. 7A ) and the lowest % main peak and % basic substances ( Fig. 8A and 9A ). This was consistent across all pH values (5.5–6.5), whereas formulations with the other 3 excipients tended to have lower % acidic material at lower pH values, which increased with increasing pH.
[0395] Capillary electrophoresis (CE)
[0396] Reduction capillary gel electrophoresis was performed to assess purity. SDS-CGE was assessed using Sciex PA800+, UV detection at 220nm, in accordance with the ATM protocol. The sample was prepared by diluting 100 μg of sample in Beckman SDS sample buffer and adding 5 μL of β-mercaptoethanol. The sample was heated at 70°C for 10 minutes. Separation occurred within 20 minutes using normal polarity, 1 minute ramp, 15kV voltage and 20psi pressure. The capillary length was 30.2cm and the length to the detector was 10.2cm. The starting material was used as a reference. An overview of the sample purity percentages is shown in Table 27. An overview of the sample impurity percentages is shown in Table 28.
[0397] Table 27. % Purity
[0398]
[0399] Table 28. % of impurities
[0400]
[0401] Non-reducing capillary gel electrophoresis was also performed to assess purity. SDS-CGE was assessed using SciexPA800+ according to the ATM protocol, with UV detection at 220nm. The sample was prepared by diluting 100μg of sample in Beckman SDS sample buffer and adding 5μL 250mM iodoacetamide. The sample was heated at 70°C for 10 minutes. Separation occurred within 20 minutes using normal polarity, 1 minute ramp-up, 15kV voltage and 20psi pressure. The capillary length was 30.2cm and the length to the detector was 10.2cm. The starting material was used as a reference. An overview of %HMW CE (NR) data is shown in Table 29. An overview of %main peak CE (NR) data is shown in Table 30. An overview of %LMW CE (NR) data is shown in Table 31.
[0402] Table 29. % HMW CE (NR)
[0403]
[0404] Table 30. % Main Peak CE (NR)
[0405]
[0406]
[0407] Table 31. %LMW CE (NR)
[0408]
[0409] As assessed by reduction CE, the % purity values of the sorbitol-only and sucrose-only formulations were maintained across the pH range (pH 5.5–6.5) in the 3-week 50°C samples ( Fig. 10A ), while the combined excipients showed higher variability to pH, with a decrease in % purity at lower values (5.5 vs. 6.5) ( Fig. 10B ).
[0410] As assessed by non-reducing CE, formulations containing sorbitol alone or sucrose alone had lower % HMW species ( ) relative to the combined excipients of NaCl with sorbitol and NaCl with sucrose in the 3-week 50°C sample. Fig.11A and 12A ). The pH level had no significant effect on the % Main Peak.
[0411] As assessed by reduced and non-reduced CE, no significant model fit the reduced CE data for the 3-week 2–8 °C samples, and for the non-reduced CE data, only the sorbitol and sucrose formulations had greater % main peak material ( Fig. 11B ).
[0412] Statistical analysis
[0413] Design Expert v9 software was used to analyze trends. A summary of the analysis is shown in Table 32. The bold models were not included in the final optimization evaluation.
[0414] Table 32. Overview of analytical models
[0415]
[0416] Excipient selection
[0417] The performance of formulations containing 250 mM sorbitol or 250 mM sucrose as excipients was more desirable than formulations containing a combination of sorbitol and NaCl or sucrose and NaCl. Therefore, the optimal formulation for A49-F3'-TriNKET-trastuzumab was determined to be 20 mM histidine, 50 mM sucrose or sorbitol and 0.01% PS80, pH 6.0.
[0418] Example 2: Pharmacokinetics (PK) of A49-F3'-TriNKET-Trastuzumab
[0419] This study was designed to determine the pharmacokinetics (PK) of A49-F3'-TriNKET-trastuzumab when administered as a 30-minute IV infusion to cynomolgus monkeys at 1 mg / kg, 10 mg / kg, or 50 mg / kg on study days 1 and 15, followed by observation periods of 13 and 6 days, respectively. A summary of the key PK parameters of A49-F3'-TriNKET-trastuzumab following the first IV infusion on day 1 to male and female cynomolgus monkeys is presented in Tables 33 and 34, respectively.
[0420] Table 33: PK parameters of A49-F3'-TriNKET-trastuzumab after the first intravenous infusion on Day 1 in male cynomolgus monkeys
[0421]
[0422] Abbreviations used in the table: AUC 0-t = area under the concentration-time curve from the time of administration to the last observation; C max = maximum serum concentration observed after administration; CL = clearance; tmax = time to maximum concentration; EOI = end of infusion; t 1 / 2 = half-life; V ss = Steady-state volume of distribution. a: time from end of IV infusion; b: does not meet acceptance criteria for estimating half-life - value is considered estimated.
[0423] Table 34: PK parameters of A49-F3'-TriNKET-trastuzumab after the first intravenous infusion on Day 1 in female cynomolgus monkeys
[0424]
[0425] Abbreviations used in the table: AUC 0-t = area under the concentration-time curve from the time of administration to the last observation; C max = maximum serum concentration observed after administration; CL = clearance; tmax = time to reach maximum concentration; t 1 / 2 = half-life; V ss = Steady-state volume of distribution. a: time from end of IV infusion; b: does not meet acceptance criteria for estimating half-life - value is considered estimated.
[0426] A summary of the key PK parameters of A49-F3'-TriNKET-trastuzumab following the second intravenous infusion on Day 15 to male and female cynomolgus monkeys is presented in Table 35 and Table 36, respectively.
[0427] Table 35: PK parameters of A49-F3'-TriNKET-trastuzumab after the second intravenous infusion on Day 15 in male cynomolgus monkeys
[0428]
[0429] Abbreviations used in the table: AUC 0-t = area under the concentration-time curve from the time of administration to the last observation; C max = maximum serum concentration observed after administration; CL = clearance; tmax = time to reach maximum concentration; t 1 / 2 = half-life; V ss = Steady-state volume of distribution. a: time from end of IV infusion; b: does not meet acceptance criteria for estimating half-life - value is considered estimated.
[0430] Table 36: PK parameters of A49-F3'-TriNKET-trastuzumab after the second intravenous infusion on Day 15 in female cynomolgus monkeys
[0431]
[0432]
[0433] Abbreviations used in the table: AUC 0-t = area under the concentration-time curve from the time of administration to the last observation; C max= maximum serum concentration observed after administration; CL = clearance; tmax = time to reach maximum concentration; t 1 / 2 = half-life; V ss = Steady-state volume of distribution. a: time from end of IV infusion; b: does not meet acceptance criteria for estimating half-life - value is considered estimated.
[0434] Appearance max The time of t is usually 15 minutes after the end of infusion (EOI). However, as shown in Tables 33 and 35, t max Also occurred at EOI on Day 1 in male cynomolgus monkeys receiving 10 mg / kg and 30 minutes after EOI on Day 15 in male cynomolgus monkeys receiving 50 mg / kg, respectively. As shown in Tables 34 and 36, t max It also occurred 1 hour after EOI on Day 15 in female cynomolgus monkeys receiving 1 mg / kg or 50 mg / kg, respectively. These data indicate that A49-F3'-TriNKET-trastuzumab declines slowly after 30 minutes of IV administration and has a long terminal half-life (t 1 / 2 ), such as more than 90 hours. The data also indicate a low serum clearance rate, and a distribution volume close to the blood volume (73.4 mL / kg) and lower than the total body water volume (693 mL / kg).
[0435] The maximum serum concentration (C max ) and the area under the concentration-time curve (AUC 0-144hr Table 37 shows the C ratio of A49-F3'-TriNKET-trastuzumab according to the dose level. max ratio and AUC ratio.
[0436] Table 37: C of A49-F3'-TriNKET-trastuzumab by dose level in male and female cynomolgus monkeys max Ratio and AUC Ratio
[0437]
[0438] As shown in Table 37, within the dose range of 1 to 50 mg / kg, C max and AUC 0-144hr The values increased almost proportionally with the increase of dose. max and AUC 0-144hrThe values were similar to those observed in male cynomolgus monkeys at exposure. The C values of A49-F3'-TriNKET-trastuzumab at the second injection on day 15 were max and AUC 0-144hr The values were similar to those after the first dose on Day 1, but were generally slightly higher at the 50 mg / kg dose level. At the 50 mg / kg dose level, based on AUC 0-144hr The cumulative ratio of values was slightly above 1, indicating that at this dose level, some accumulation occurred following repeated IV infusion dosing of A49-F3'-TriNKET-trastuzumab.
[0439] Furthermore, none of the samples from A49-F3'-TriNKET-trastuzumab treated animals were confirmed to be anti-drug antibody positive, thus no test article related anti-drug antibodies were observed in this study.
[0440] Example 3: Treatment of locally advanced or metastatic solid tumors using A49-F3'-TriNKET-trastuzumab
[0441] Purpose
[0442] This clinical study is designed to have two stages: a dose escalation phase, followed by an efficacy expansion cohort phase. The main purpose of the dose escalation phase of the study is to evaluate the safety and tolerability of A49-F3'-TriNKET-trastuzumab, and to determine the highest tolerated dose of A49-F3'-TriNKET-trastuzumab in patients with advanced (unresectable, recurrent or metastatic) solid tumors who do not have effective standard therapy or have relapsed or are intolerant to standard therapy. The main purpose of the efficacy expansion cohort phase of the study is to evaluate the overall response rate (ORR) by an independent endpoint review committee (IERC) according to the modified response evaluation criteria in solid tumors version 1.1 (mRECIST 1.1).
[0443] The secondary objectives of this clinical study are to:
[0444] - Characterize the pharmacokinetics of A49-F3'-TriNKET-trastuzumab;
[0445] - To evaluate the immunogenicity of A49-F3'-TriNKET-trastuzumab and correlate it with exposure and clinical activity;
[0446] - Duration of response (DOR) of A49-F3'-TriNKET-trastuzumab assessed by IERC;
[0447] - Best Overall Response (BOR) assessment by the IERC;
[0448] - Progression-free survival (PFS) of A49-F3'-TriNKET-trastuzumab as assessed by IERC;
[0449] - To assess overall survival (OS); and
[0450] - To evaluate the safety of combination therapy of A49-F3'-TriNKET-trastuzumab and pembrolizumab.
[0451] Study Design
[0452] This study is a Phase I / II open-label dose-escalation study and a sequential parallel-group efficacy extension study designed to determine the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of A49-F3'-TriNKET-trastuzumab alone and in combination with pembrolizumab. This study consists of two parts:
[0453] (1) The dose escalation phase (Phase I) is divided into three stages:
[0454] (A) Accelerated titration;
[0455] (B) “3+3” dose escalation; and
[0456] (C) Safety / pharmacokinetics (PK) / pharmacodynamics (PD) expansion cohort
[0457] (2) The efficacy extension group part (Phase II) is divided into the following four groups:
[0458] (A) Urothelial bladder cancer (UBC)
[0459] (B) Metastatic breast cancer (MBC)
[0460] (C) Basket solid tumors with high HER2 expression (HER2 3+)
[0461] (D) Combination therapy with pembrolizumab.
[0462] In an exemplary embodiment, patients recruited in the dose escalation part and efficacy expansion (UBC, MBC or Basket [HER23+] cohort) part receive A49-F3'-TriNKET-trastuzumab as a monotherapy by 1 hour intravenous infusion in a 4-week treatment cycle. For treatment cycle 1, patients receive A49-F3'-TriNKET-trastuzumab on days 1, 8 and 15. For treatment cycle 2 and subsequent cycles, patients receive A49-F3'-TriNKET-trastuzumab once every two weeks (e.g., day 1 and day 15) until confirmed progression, unacceptable toxicity (as described in this example under the "dose limiting toxicity (DLT)" section) or any reason for withdrawal from the trial or investigational medicinal product (IMP). Patients enrolled in the combination therapy with pembrolizumab cohort of the efficacy expansion cohort portion received A49-F3'-TriNKET-trastuzumab as a 1-hour IV infusion and pembrolizumab as a 30-minute IV infusion in a 3-week treatment cycle. In an exemplary embodiment, 200 mg of pembrolizumab was administered according to the instructions together with A49-F3'-TriNKET-trastuzumab.
[0463] For treatment cycle 1, patients received A49-F3'-TriNKET-trastuzumab and pembrolizumab on day 1 and A49-F3'-TriNKET-trastuzumab alone on day 8. For treatment cycle 2 and subsequent cycles, patients received A49-F3'-TriNKET-trastuzumab and pembrolizumab every 3 weeks on day 1 of each cycle until confirmed progression, unacceptable toxicity (as described in this example under the "Dose Limiting Toxicity (DLT)" section), or any reason for withdrawal from the trial or IMP.
[0464] Patients who experienced a confirmed complete response (CR) received treatment for up to 12 months after confirmation as determined by the investigator. Treatment beyond 12 months was permitted if the investigator believed, after discussion with the sponsor's medical monitor, that the patient would benefit from continued treatment.
[0465] Fig.14A -B is a schematic diagram of the clinical trial design. Fig.14A The trial design used for the dose-escalation phase is described. Fig. 14B The trial design used for the efficacy expansion cohort phase is described.
[0466] Inclusion criteria
[0467] The overall inclusion criteria for patients recruited in any cohort in the clinical studies of this example include:
[0468] -Have signed written informed consent;
[0469] -Age ≥18 years (including male and female patients);
[0470] - Patients with histologically or cytologically confirmed locally advanced or metastatic solid tumors for which standard therapy does not exist or has failed. The primary tumor must have HER2 expression confirmed by immunohistochemistry;
[0471] - Have an ECOG performance status of 0 or 1 at study entry and an expected life expectancy of at least 3 months;
[0472] - Baseline left ventricular ejection fraction (LVEF) ≥ 55% as measured by echocardiography (preferably) or multiple gated acquisition (MUGA) scanning;
[0473] - With a white blood cell (WBC) count ≥ 3 × 10 9 / L and absolute neutrophil count (ANC) ≥ 1.5 × 10 9 / L, lymphocyte count ≥ 0.5 × 10 9 / L, platelet count ≥75×10 9 / L and adequate hematologic function as defined by hemoglobin ≥9 g / dL (blood transfusion may have been performed);
[0474] - Have adequate liver function defined by total bilirubin level ≤1.5× upper limit of normal (ULN), aspartate aminotransferase (AST) level ≤2.5×ULN, and alanine aminotransferase (ALT) level ≤2.5×ULN, or AST and ALT levels ≤5×ULN for patients with confirmed disease metastasis to the liver;
[0475] - Have adequate renal function as defined by creatinine clearance >50 mL / min estimated according to the Cockcroft-Gault formula; and
[0476] - For women of childbearing potential (WOCBP), use effective contraception as defined by the WHO guidelines for 1 “highly effective” method or 2 “effective” method.
[0477] For patients enrolled in the accelerated titration or "3+3" dose escalation phase of the dose escalation portion described in this example, additional inclusion criteria included:
[0478] - Have objective evidence of disease, but measurable lesions are not required for participation; and
[0479] - Have archived tumor biopsy available (≤6 months, at least 8 slides) or fresh biopsy obtained within the screening window (at least 10 slides and 3 cores).
[0480] For patients enrolled in the safety / PK / PD expansion cohort phase of the dose escalation portion described in this example, additional inclusion criteria included:
[0481] - Have a fresh tumor biopsy sample obtained within the screening window to obtain a formalin-fixed paraffin-embedded (FFPE) paraffin block or sufficient unstained slides to perform IHC (at least 3 unstained slides), with a total of at least 12 slides and with at least 3 fresh cores; and
[0482] - HER2 at least 1+ by IHC at Screening.
[0483] For patients recruited in the UBC expansion cohort described in this Example, additional inclusion criteria included:
[0484] - Locally advanced or metastatic transitional cell carcinoma with histological or cytological confirmation of the urothelium (including renal pelvis, ureter, urothelium, urethra);
[0485] - Radiographic disease progression after the last line of treatment;
[0486] - Patients who have received one (and no more than one) platinum-containing regimen (e.g., platinum plus another agent such as gemcitabine, methotrexate, vinblastine, doxorubicin, etc.) for inoperable locally advanced or metastatic urothelial carcinoma who have radiographic progression or recurrence within 6 months after the last administration of a platinum-containing regimen as adjuvant therapy, which will be considered a failure of the first-line platinum-containing regimen;
[0487] - Have received treatment with a checkpoint inhibitor (i.e., anti-PD-1 or anti-PD-L1 antibody) with radiographic progression (optionally have received a combination of platinum-based therapy and PD-1 / PD-L1-based therapy);
[0488] - HER2 expression of at least 1+ by IHC; and
[0489] - Have a fresh tumor biopsy sample obtained within the screening window to obtain formalin-fixed paraffin-embedded (FFPE) paraffin blocks or sufficient unstained slides for IHC (at least 3 unstained slides) with a total of at least 12 slides and with at least 3 fresh cores.
[0490] For patients recruited in the MBC expansion cohort described in this example, additional inclusion criteria included:
[0491] - MBC with histological confirmation;
[0492] - Have received no more than 3 prior cytotoxic therapies for metastatic disease;
[0493] - Received taxanes and anthracyclines unless anthracyclines are contraindicated;
[0494] - Have a tumor score of 1+ or 2+ by IHC, and if the score is 2+, the tumor must be adjudicated for the presence of ERRB2 amplification by an FDA-approved method;
[0495] - Progression (radiological) after last line of systemic therapy; and
[0496] - Have a fresh tumor biopsy sample obtained within the screening window to obtain formalin-fixed paraffin-embedded (FFPE) paraffin blocks or sufficient unstained slides for IHC (at least 3 unstained slides) with a total of at least 12 slides and with at least 3 fresh cores.
[0497] For patients recruited in the basket (HER2 3+) cohort described in this example, additional inclusion criteria included:
[0498] - Any solid tumor other than breast or gastric cancer, history of intratumoral ERRB2 amplification and one of the following: 1) confirmed HER2 3+ by IHC in the most recent biopsy within 6 months of radiographic progression after the last line of therapy, or 2) HER 3+ by IHC during the screening window;
[0499] - Have received at least one line of approved or established therapy; and
[0500] - Have a fresh tumor biopsy sample obtained within the screening window to obtain formalin-fixed paraffin-embedded (FFPE) paraffin blocks or sufficient unstained slides for IHC (at least 3 unstained slides) with a total of at least 12 slides and with at least 3 fresh cores.
[0501] For patients enrolled in the combination therapy cohort phase with pembrolizumab of the efficacy expansion part described in this example, additional inclusion criteria included:
[0502] - Eligible to receive pembrolizumab for a malignancy of epithelial origin per the labeling; and
[0503] - Have a fresh tumor biopsy sample obtained within the screening window to obtain formalin-fixed paraffin-embedded (FFPE) paraffin blocks or sufficient unstained slides for IHC (at least 3 unstained slides) with a total of at least 12 slides and with at least 3 fresh cores.
[0504] Exclusion criteria
[0505] The exclusion criteria for patients recruited in the clinical study of this example included:
[0506] - Concurrent treatment with unlicensed medications, including:
[0507] ○ Immunotherapy, immunosuppressive drugs (including chemotherapy or systemic corticosteroids, except for short-term treatment of allergic reactions or treatment of irAEs), or other experimental medicinal products.
[0508] ■Exceptions:
[0509] ● Short-term administration of systemic steroids (e.g., for the management of allergic reactions or irAEs) is permitted;
[0510] ● Steroids with no or very low systemic effects (topical, inhaled) are allowed;
[0511] ○ TKI targeting HER2 or any recombinant molecule targeting HER2 or NKG2D;
[0512] ○ Growth factors (granulocyte colony stimulating factor or granulocyte macrophage colony stimulating factor).
[0513] ■Exceptions:
[0514] ■Erythropoietin and erythropoietin analogs may be prescribed at the investigator's discretion;
[0515] ○ Treatment with bisphosphonates or denosumab was not permitted.
[0516] ■Exceptions: Use of bisphosphonates or denosumab is permitted unless it is started more than 14 days before the first dose of A49-F3'-TriNKET-trastuzumab.
[0517] - Prior treatment with drugs that specifically target the HER2 pathway.
[0518] ■Exceptions: mAbs or tyrosine kinase inhibitors (TKIs) are acceptable as long as the washout period is exceeded (4 weeks for mAbs or protein therapeutics and 2 weeks for TKIs);
[0519] - Concurrent anticancer therapy (e.g., cytoreductive therapy, radiation therapy (except palliative bone-directed radiation therapy), immunotherapy, or cytokine therapy other than erythropoietin), major surgery (excluding prior diagnostic biopsy), concomitant systemic therapy with steroids or other immunosuppressants, or use of any study drug within 28 days prior to the start of study treatment. Short-term administration of systemic steroids (e.g., for the management of allergic reactions or irAEs) is permitted. Patients receiving bisphosphonates are eligible as long as treatment is started at least 14 days before the first dose of A49-F3'-TriNKET-trastuzumab;
[0520] - Previous malignant disease other than the target malignancy to be investigated in this study within the past 3 years, excluding basal or squamous cell carcinoma of the skin or cervical cancer in situ;
[0521] - Rapid disease progression;
[0522] - Active or history of central nervous system (CNS) metastases;
[0523] - Receiving any organ transplant, including autologous or allogeneic stem cell transplant;
[0524] - Significant acute or chronic infection (including historical positive test for human immunodeficiency virus (HIV), or active or latent hepatitis B or active hepatitis C detected during the screening window);
[0525] - Existing autoimmune disease (except patients with vitiligo) or clinically relevant immunodeficiency (e.g., dysgammaglobulinemia or congenital immunodeficiency) requiring treatment with systemic immunosuppressants for more than 28 days within the past 3 years, or fever within 7 days of Day 1;
[0526] - Known severe hypersensitivity reaction to mAb (≥Grade 3 NCI-CTCAE v5.0), any history of anaphylaxis, or uncontrolled asthma (e.g., 3 or more features of partially controlled asthma);
[0527] - Ongoing toxicity related to prior therapy > Grade 1 NCI-CTCAE v5.0, but alopecia and sensory neuropathy ≤ Grade 2 are acceptable;
[0528] - Women are pregnant or breastfeeding during the study;
[0529] - Known alcohol or drug abuse;
[0530] - Serious heart disease or medical conditions, including but not limited to:
[0531] ○ History of New York Heart Association Class III or IV heart failure or systolic dysfunction (LVEF < 55%);
[0532] ○ High-risk uncontrolled arrhythmias, i.e. tachycardia with a resting heart rate >100 / min;
[0533] ○ Significant ventricular arrhythmia (ventricular tachycardia) or higher-grade AV block (second-degree
[0534] AV block type 2 (Mobitz 2) or third-degree AV block);
[0535] ○Angina pectoris requiring anti-anginal medication;
[0536] ○Clinically significant valvular heart disease;
[0537] ○ Evidence of transmural infarction on ECG;
[0538] ○ Poorly controlled hypertension (defined as systolic blood pressure >180 mmHg or diastolic blood pressure >100 mmHg);
[0539] ○ Clinically relevant uncontrolled cardiac risk factors, clinically relevant pulmonary disease, or any clinically relevant medical condition that the investigator believes may limit participation in this study;
[0540] - Any other significant illness that the investigator believes may impair the patient's ability to participate in this study (e.g., inflammatory bowel disease);
[0541] - Any mental illness that would impede the understanding or provision of informed consent;
[0542] - is legally incompetent or has limited legal capacity; or
[0543] - Unable to sign informed consent, including compliance with the requirements and restrictions outlined in the Informed Consent Form (ICF) and this protocol.
[0544] Dose-limiting toxicity (DLT)
[0545] Safety and tolerability were evaluated in each cohort. Dose-limiting toxicities (DLTs) were assessed in the first 21 days for patients enrolled in the dose-escalation part and in the pembrolizumab combination cohort. A DLT was a grade ≥ 3 adverse drug reaction according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) v5.0 that occurred during the DLT evaluation period in the dose-escalation cohort. An adverse drug reaction may be an adverse event that the investigator and / or sponsor suspects is related to A49-F3'-TriNKET-trastuzumab. For patients enrolled in the dose-escalation part and in the pembrolizumab combination cohort, a DLT was defined as any of the following occurring within the first 21 days of treatment:
[0546] - Any Grade 3 to 4 non-hematologic toxicity, except for:
[0547] i. Grade 3 nausea, vomiting, and diarrhea lasting < 72 hours without maximal medical treatment;
[0548] ii. Grade 4 vomiting and diarrhea lasting < 72 hours without maximal medical therapy;
[0549] iii. Grade 3 fatigue < 5 days;
[0550] iv. Grade 3 hypertension in the absence of maximal medical therapy.
[0551] - Any of the following hematologic toxicities:
[0552] i. Grade 4 neutropenia > 5 days;
[0553] ii. Grade 3 thrombocytopenia with bleeding;
[0554] iii. Grade 4 thrombocytopenia.
[0555] -With the exception of the following:
[0556] i. A single laboratory value outside the normal range that is unlikely to be related to study treatment in the opinion of the investigator, is not of any clinical relevance, and resolves to ≤ Grade 1 with appropriate medical management within 7 days.
[0557] For all dose cohorts, the DLT observation period may include the first 3 weeks of treatment with the investigational medicinal product in the dose escalation portion for all patients whose data are used to implement the dose escalation algorithm to determine the maximum tolerated dose (MTD). Additional patients may be recruited during the dose escalation phase and adverse events may be collected; optionally, these patients may not have a specific DLT observation period. The Safety Monitoring Committee may take a conservative approach to attributing the relevance of treatment-related toxicity to the drug. Serious adverse events related to treatment are attributed to the drug unless there is an obvious relationship to the underlying disease or recognized comorbidities.
[0558] Safety was assessed by recording, reporting, and analyzing baseline medical conditions, adverse events (AEs), physical examination results (including vital signs and determination of left ventricular ejection fraction), electrocardiograms, and laboratory tests.
[0559] Dosage and administration
[0560] A49-F3'-TriNKET-trastuzumab dose escalation
[0561] At the beginning of the trial, each patient is assigned a certain dose level. The dose level is adjusted as needed to adapt to weight changes. After all patients in the cohort reach the 21st day (DLT assessment period), it is decided to increase to the next dose level based on the safety assessment. In certain embodiments, patients receive IV infusions of A49-F3'-TriNKET-trastuzumab within 1 hour (e.g., 50 to 70 minutes) once every two weeks. The dose of A49-F3'-TriNKET-trastuzumab is calculated based on the patient's weight determined the day before or on the day of each drug administration. In an exemplary embodiment, the starting dose of A49-F3'-TriNKET-trastuzumab is 5.2x 10 -5 mg / kg, and the first 8 dose levels (DL) followed an accelerated design of dose escalation and consisted of a single patient cohort with no more than 3.3-fold incremental steps. In the event of DLT, the dose escalation was switched to a "3+3" design, in which 5 additional patients were added at the dose level where DLT was observed.
[0562] Similar to the accelerated titration phase, dose escalation in the "3+3" escalation phase was performed with no more than 3.3-fold increases between dose levels. Table 38 summarizes the starting dose determined by body weight (mg / kg) and dose level (DL) of the escalation schedule.
[0563] Table 38: Exemplary DL in the "accelerated titration" and "3+3" dose escalation phases (in mg / kg body weight)
[0564]
[0565] In an exemplary embodiment, three patients are initially recruited in a given dose cohort during the "3+3" phase. After the first patient is recruited, the second patient is recruited no earlier than 2 days after the second injection of A49-F3'-TriNKET-trastuzumab to the first patient. After at least 48 hours of follow-up after A49-F3'-TriNKET-trastuzumab is administered to the second patient, the first administration of A49-F3'-TriNKET-trastuzumab is provided to the third patient. More than 3 patients (such as in the case of observing DLT in the first 3 patients of a specific cohort or after 3 patients have been recruited at DL 7) can be recruited in a specific dose cohort without any predetermined time interval between the start of treatment, unless an infusion reaction or cytokine release syndrome or any grade 3 or higher treatment-related toxicity is observed during the treatment of the first 3 patients. In this case, the same predetermined time interval for the first 3 patients is repeated. In the case of no DLT observed in any of these patients, the study continues to recruit additional 3 patients in the next higher dose cohort. If 1 patient develops DLT at a specific dose, an additional 3 patients are recruited in the same dose group. In a specific dose group, the occurrence of DLT in more than 1 patient out of 6 patients indicates that the MTD has been exceeded and further dose escalation is not continued (see the Dose-Limiting Toxicity (DLT) section in this example).
[0566] In an exemplary embodiment, once the safety of DL 10 (1.6 mg / kg) is established by the Safety Monitoring Committee, up to 10 additional patients are treated with DL 9 (up to 16 patients per DL in total) to increase the safety, PK, and PD databases under this DL, while incrementing with DL 11 in accordance with the "3+3" rule. A similar process is applied to DLs 10 to 13. The increment in the safety / PK / PD expansion cohort phase continues without the use of a scheduled observation period. Mandatory tumor biopsies are performed at screening (within 30 days before the first study drug dose) and within 1 to 7 days before the sixth study drug dose. Safety information is typically generated during the treatment of these patients and is communicated to the Safety Monitoring Committee. The same process is implemented for subsequent DLs of the safety / PK / PD expansion cohort.
[0567] Efficacy expansion cohort dose
[0568] As mentioned earlier in this Example, there are 4 efficacy expansion cohorts: UBC; MBC; basket (HER2 3+) cohort, which includes patients with solid tumors with high HER2 expression who have received at least one first line of treatment consisting of established or approved therapies; and combination therapy with pembrolizumab. Escalation in these cohorts begins as follows:
[0569] - In the first three cohorts (UBC, MBC and basket (HER2 3+), 3 monotherapy cohorts were initiated after dose determination and planning of A49-F3'-TriNKET-trastuzumab.
[0570] - After the Safety Monitoring Board established the safety of DL11, an escalation of safety run-in was initiated for the combination of A49-F3'-TriNKET-trastuzumab and pembrolizumab. The dose of A49-F3'-TriNKET-trastuzumab to be combined with pembrolizumab was declared safe during the "3+3" dose escalation using A49-F3'-TriNKET-trastuzumab as monotherapy and then tested in combination with pembrolizumab (subsequent DLs during the dose escalation period were deemed safe by the Safety Monitoring Board).
[0571] In the first three efficacy expansion cohorts, patients received A49-F3'-TriNKET-trastuzumab as monotherapy. A maximum of 40 patients could be enrolled in each of the three expansion cohorts, and a futility analysis was performed after the first 20 patients in each cohort had been observed for at least 3 months. Mandatory tumor biopsies were performed at screening (within 30 days before the first dose of study drug) and within 1 to 7 days before the sixth dose of study drug.
[0572] In the efficacy expansion cohort of combination therapy with pembrolizumab, patients received DL 10 of A49-F3'-TriNKET-trastuzumab (as a 1-hour IV infusion) and the approved dose of pembrolizumab 200 mg (as a 30-minute IV infusion) in 3-week treatment cycles. This safety run-in exercise followed the same "3+3" design as previously described. Patients in this study met the patient inclusion criteria described in the "Inclusion Criteria" section.
[0573] Safety during the efficacy expansion cohort (A49-F3'-TriNKET-trastuzumab monotherapy cohort): All safety information from participating patients is continuously monitored by the safety monitoring committee. In an exemplary embodiment, a group of 20 patients is recruited and followed up by the safety monitoring committee for 4 weeks. Subsequently, such a safety review is performed within 4 weeks after 40 patients are treated and followed up for at least 4 weeks. Then, a similar process is performed each time 40 patients are recruited and followed up for at least 4 weeks.
[0574] Safety during the efficacy expansion cohort (A49-F3'-TriNKET-trastuzumab plus pembrolizumab combination therapy cohort): Similar to what was described for the "3+3" dose escalation portion, all safety information from participating patients was continuously monitored by the Safety Monitoring Board. For each patient, safety and tolerability data were reviewed by the Safety Monitoring Board during the 21-day DLT assessment period, and progression to further doses was dependent on the Safety Monitoring Board. If combination therapy could be safely continued (based on the decision of the Safety Monitoring Board), a cohort of 20 patients was recruited and followed for 3 weeks.
[0575] end
[0576] The study was designed to evaluate primary and secondary endpoints to assess the clinical benefit of A49-F3'-TriNKET-trastuzumab, optionally in combination with pembrolizumab, as a treatment for patients with locally advanced or metastatic solid tumors.
[0577] Primary End Point and Analysis of Primary End Point
[0578] In the dose escalation part, the occurrence of DLT in the first three weeks of treatment was measured as the primary endpoint. The highest tolerated dose (MTD) was determined during the dose escalation part, which was defined as the highest dose level (DL) at which no more than 1 patient experienced a DLT event among the 6 patients treated. The highest tolerated dose was determined by individual patient data from the dose escalation part. In addition, in order to perform the final statistical analysis, the following parameters can be analyzed:
[0579] -The number and proportion of patients in the DLT population who experienced a DLT during the first DLT assessment period at each dose level;
[0580] - The number and proportion of treatment-emergent adverse events experienced by patients in the DLT population during the first DLT evaluation period at each dose level.
[0581] For the efficacy expansion cohort, the confirmed overall response rate adjudicated by an independent endpoint review committee (IERC) according to mRECIST 1.1A was measured as the primary endpoint. The overall response rate was defined as the best response achieved at all tumor assessment visits from the start of trial treatment until documented disease progression, taking into account the confirmation requirements described below. Confirmation of response according to mRECIST 1.1 was required for complete response and partial response. Confirmation may be assessed at the regularly scheduled 6-week assessment interval, but no earlier than 4 weeks after the start of documentation of a complete response or partial response. Confirmation of a partial response may be confirmed at a later assessment than the next assessment after the start of documentation of a partial response.
[0582] Best overall response of stable disease may require an overall response of stable disease to be determined at a time point of at least 37 days after the start of study treatment. The response and best overall response at each scheduled tumor assessment are listed for each patient.
[0583] Secondary End Points and Analysis of Secondary End Points
[0584] Secondary endpoints of the study may include the following parameters:
[0585] - Number, severity, and duration of treatment-emergent adverse events across all dose groups / indications according to NCI-CTCAE v5.0;
[0586] - Number, severity, and duration of treatment-related adverse events according to NCI-CTCAE v5.0;
[0587] - Duration of response according to mRECIST 1.1 as assessed by the investigator;
[0588] -pharmacokinetic profile;
[0589] - Best overall response according to mRECIST 1.1 as assessed by the investigator;
[0590] - Progression-free survival according to mRECIST 1.1 as assessed by the investigator;
[0591] - Overall survival;
[0592] -Progressive disease profile;
[0593] - serum titer of anti-A49-F3'-TriNKET-trastuzumab antibodies;
[0594] - HER2 expression on tumor tissue;
[0595] - ERBB2 status (amplified / unamplified, mutated / unmutated);
[0596] - Unconfirmed response according to mRECIST 1.1 at Week 13 (for the safety / PK / PD expansion cohort);
[0597] - Progression-free survival according to mRECIST 1.1 according to IERC; Duration of response according to mRECIST 1.1 according to IERC (for the efficacy expansion cohort).
[0598] Efficacy parameters: The main efficacy parameter in the extension part is the best overall response determined according to mRECIST 1.1. According to the investigator's assessment, ORR will be determined according to mRECIST 1. The overall response rate is evaluated throughout the trial period. For the best overall response of partial response or complete response, confirmation of response is required according to mRECIST 1.1. The response and best overall response at each planned tumor assessment are listed for each patient. The number and proportion of overall response rates (defined as complete response + partial response) are listed according to the group. For the basket group of high HER2, the number and proportion of overall response rates are listed for each tumor type that recruits more than 5 patients and treats for 4 weeks. Tumor types represented by less than 5 patients (1 patient to 4 patients) are represented as a subgroup. For each patient with a confirmed response in the expansion group, the duration of response is calculated according to mRECIST 1.1 and analyzed in all groups using the Kaplan-Meier method. Progression-free survival and overall survival times are presented in the patient tables and were analyzed with the use of the Kaplan–Meier method in the full analysis set of the expansion cohort that amassed the full planned number of patients.
[0599] Pharmacokinetics: Serum concentrations of A49-F3'-TriNKET-trastuzumab were determined by a validated method. The following PK parameters were estimated and reported:
[0600] - AUC0→t: area under the concentration-time curve from the time of dosing to the last observation time (calculated by linear trapezoidal summation);
[0601] - AUC0→∞: area under the curve extrapolated from the dosing time to infinity (calculated by linear trapezoidal summation and extrapolated to infinity using Clast / λz);
[0602] -λz: terminal elimination rate constant. The value of λz is determined from the slope of the regression line of log(concentration) versus time using the following constraints: (i) there must be at least 3 consecutive measurable concentrations, (ii)
[0603] All concentrations must decrease over time, and (iii) the correlation coefficient (r) of the regression must be ≥ 0.95;
[0604] -Cmax: the highest serum concentration observed after administration;
[0605] -tmax: the time at which Cmax occurs; and
[0606] -t1 / 2: Elimination half-life, determined to be 0.693 / λz.
[0607] PK parameters were summarized using descriptive statistics. Individual as well as mean concentration-time plots were depicted. Unresolved missing data were imputed when the completeness of the analysis was compromised. Conservatism was used for data imputation.
[0608] Serum titers of anti-drug antibodies: Implementation and execution of a safe immunogenicity testing strategy consistent with:
[0609] - Immunogenicity assessment of therapeutic proteins of biotechnological origin (see Guideline on Immunogenicity Assessment of Therapeutic Proteins, 18 May 2017 EMEA / CHMP / BMWP / 14327 / 2006 Rev 1, Committee for Medicinal Products for Human Use (CHMP); European Medicines Agency);
[0610] - Immunogenicity assessment of mAbs intended for in vivo clinical use (see “Guideline on Immunogenicity Assessment of Monoclonal Antibodies Intended for In Vivo Clinical Use”, 24 May 2012 EMA / CHMP / BMWP / 86289 / 2010, Committee for Medicinal Products for Human Use (CHMP); European Medicines Agency);
[0611] - FDA (2009, draft) Guidance for Industry: Assay Development for Immunogenicity Testing of Therapeutic Proteins.
[0612] A qualified method for detecting anti-drug (i.e., anti-A49-F3'-TriNKET-trastuzumab) antibodies in human serum in the presence of excess drug using an acid dissociation step was applied. No drug removal was required after acid treatment. The ADA titer of positive samples was determined.
[0613] Biomarkers: Summary statistics for biomarkers at all pre-planned time points are presented for each DL or cohort. Changes from baseline are presented when applicable. Changes over time are presented on a per-patient basis.
[0614] Safety Analysis: Exposure to A49-F3'-TriNKET-trastuzumab was characterized by duration (weeks), number of doses, cumulative dose (mg / kg), dose intensity (mg / kg / week), relative dose intensity (actual dose administered / planned dose), number of dose reductions, and number of dose delays. Safety analyses were performed on the safety population. Safety endpoints were tabulated by DL and cohort using descriptive statistics. Safety assessments were based on a review of adverse event rates, including adverse events of special concern, adverse drug reactions, and changes in vital signs, electrocardiograms, body weight, and laboratory values (hematology and serum chemistry). The treatment period was defined as the time from the first dose of study treatment to the last dose of study treatment + 30 days or the earliest date of new anticancer treatment - 1 day, whichever occurred first.
[0615] Adverse Events (AEs): Adverse events were coded according to the Medical Dictionary for Regulatory Activities (MedDRA). The severity of AEs was graded using the NCI-CTCAE v5.0 toxicity grading scale. Treatment-emergent adverse events (TEAEs) were those with an onset date that was within the treatment period or worsening of the event within the treatment period. The incidence of TEAEs regardless of attribution and AEs defined as possibly related to A49-F3'-TriNKET-trastuzumab were summarized by preferred term and system organ class and described by intensity and relationship to A49-F3'-TriNKET-trastuzumab. All premature / permanent discontinuations were summarized by the main reason for study withdrawal. The duration of a TEAE was defined as the time from onset to resolution to baseline. The duration of Grade 3 and 4 was defined by the time period during which a specific TEAE reached Grade 3 or 4 severity. Descriptive statistics were examined for evidence of dose-related ADRs.
[0616] Laboratory variables: Laboratory results were categorized by grade according to NCI-CTCAE. The worst trial grade after the first trial treatment was summarized. The change in toxicity grade from the first treatment to the highest grade was presented. Results for variables that are not part of the NCI-CTCAE are presented as below normal limits, within normal limits, or above normal limits. Only patients with post-baseline laboratory values were included in these analyses.
[0617] PE (including vital signs, 12-lead ECG, and transthoracic echocardiogram (TT-ECHO) / MUGA): PE data were recorded, including vital signs (temperature, respiratory rate, heart rate, and blood pressure) and lead ECG.
[0618] Incorporated by Reference
[0619] The entire disclosure of each patent document and scientific article mentioned herein is incorporated by reference for all purposes.
[0620] Equivalence
[0621] The present disclosure may be embodied in other specific forms without departing from its spirit or essential characteristics. Therefore, the aforementioned embodiments should be considered in all cases to be illustrative rather than limiting the disclosure described herein. The various structural elements of different embodiments and the various disclosed method steps can be used in various combinations and arrangements, and all such variations are considered to be forms of the present disclosure. Therefore, the scope of the present disclosure is indicated by the appended claims rather than the above description, and it is intended that all changes within the meaning and equivalent scope of the claims be included therein.
Claims
1. Use of a multispecific binding protein in the preparation of a medicament for treating cancer in a subject in need thereof on day 1, day 8, and day 15, but not on day 22, of an initial 4-week treatment cycle, and on day 1 and day 15 of each subsequent treatment cycle in one or more subsequent 4-week treatment cycles, wherein the multispecific binding protein comprises: (a) Fab binding to NKG2D; (b) a scFv that binds to HER2; and (c) Antibody Fc domain that binds to CD16.
2. The use of claim 1, wherein the multispecific binding protein is administered by intravenous infusion in an amount selected from the group consisting of 5 mg / kg, 10 mg / kg, 15 mg / kg and 20 mg / kg per dose.
3. The use according to claim 1, wherein the treatment further comprises administering an anti-PD-1 antibody to the subject.
4. The use according to claim 1, wherein the cancer is HER2 positive according to ASCO / CAP guidelines.
5. The use according to claim 1, wherein the cancer is a locally advanced or metastatic solid tumor.
6. The use according to claim 1, wherein the HER2 level in the cancer is scored as 3+ when determined by immunohistochemistry.
7. The use according to claim 1, wherein the HER2 level in the cancer is scored as 2+ or 3+ when determined by immunohistochemistry.
8. The use according to claim 7, wherein the cancer has amplification of the ERBB2 gene.
9. The use according to claim 1, wherein the cancer has amplification of the ERBB2 gene.
10. The use according to claim 6 or 8, wherein the cancer is gastric cancer.
11. The use according to claim 6 or 8, wherein the cancer is esophageal cancer.
12. The use according to claim 6 or 8, wherein the cancer is breast cancer.
13. The use according to claim 1, wherein the Fab comprises: (a) a heavy chain variable domain comprising CDR1, CDR2 and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 168, 96 and 169, respectively; and (b) a light chain variable domain comprising CDR1, CDR2 and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 99, 100 and 101, respectively.
14. The use according to claim 13, wherein the heavy chain variable domain of the Fab comprises an amino acid sequence at least 90% identical to SEQ ID NO: 94, and the light chain variable domain of the Fab comprises an amino acid sequence at least 90% identical to SEQ ID NO:
98.
15. The use according to claim 1, wherein the scFv comprises: (a) a heavy chain variable domain comprising CDR1, CDR2 and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 115, 116 and 117, respectively; and (b) a light chain variable domain comprising CDR1, CDR2 and CDR3 sequences represented by the amino acid sequences of SEQ ID NOs: 119, 120 and 121, respectively.
16. The use according to claim 15, wherein the heavy chain variable domain of the scFv comprises an amino acid sequence at least 90% identical to SEQ ID NO: 195, and the light chain variable domain of the scFv comprises an amino acid sequence at least 90% identical to SEQ ID NO:
196.
17. The use according to claim 15, wherein the light chain variable domain of the scFv is connected to the N-terminus of the heavy chain variable domain of the scFv via a flexible linker comprising the amino acid sequence of SEQ ID NO:
143.
18. The use according to claim 15, wherein the heavy chain variable domain of the scFv comprises a cysteine residue at position 44, the light chain variable domain of the scFv comprises a cysteine residue at position 100, the amino acid positions are numbered according to Kabat, and wherein the two cysteine residues form a disulfide bond.
19. The use according to claim 1, wherein the antibody Fc domain comprises a first antibody Fc sequence connected to the heavy chain portion of the Fab and a second antibody Fc sequence connected to the scFv via a hinge comprising Ala-Ser, and wherein the first and second antibody Fc sequences comprise different mutations that promote heterodimerization.
20. The use according to claim 19, wherein the first and second antibody Fc sequences each comprise the hinge and CH2 domains of a human IgG1 antibody.
21. The use of claim 1, wherein the multispecific binding protein comprises: (a) a first polypeptide comprising the amino acid sequence of SEQ ID NO: 141; (b) a second polypeptide comprising the amino acid sequence of SEQ ID NO: 140; and (c) a third polypeptide comprising the amino acid sequence of SEQ ID NO:
142.
22. A pharmaceutical preparation comprising: (a) a multispecific binding protein comprising: (i) Fabs that bind to NKG2D; (ii) a single chain variable fragment (scFv) that binds HER2; and (iii) antibody Fc domain; (b) histidine; (c) sugars or sugar alcohols; and (d) polysorbates, and has a pH of 5.5 to 6.5.
